# Chapter 110: Opioid Intoxication

## The Biological and Neurological Basis of Opioid Intoxication

## Introduction

Opioid intoxication is a transient clinical state resulting from the administration of opioids, characterized by significant disturbances in consciousness, cognition, perception, affect, and behavior (Sarkar et al., 2023; Fareed et al., 2011). While often sought for its analgesic and euphoric properties, this state carries substantial risks, including profound central nervous system (CNS) depression, respiratory failure, and death (Jones et al., 2023; Dolinak, 2017). The recent and dramatic increase in the misuse of prescription analgesics and the widespread availability of illicit opioids such as heroin and synthetic analogues like fentanyl have precipitated a global public health crisis, marked by an epidemic of overdoses and fatalities (Schuckit, 2016; Patel & Kosten, 2019; Lutfy, 2020; Dolinak, 2017).

Understanding the biological and neurological underpinnings of opioid intoxication is paramount for both clinical management and the development of effective interventions. Opioids, whether endogenous peptides or exogenous compounds, exert their powerful effects by interacting with a specific family of receptors distributed throughout the central and peripheral nervous systems (Lambert, 2023; Thakrar & Rastegar, 2025; Bhatt & Gill, 2016). The acute state of intoxication represents one point on a complex continuum that extends from initial, often recreational or therapeutic use, to the chronic, relapsing brain disease of opioid use disorder (OUD) (Kosten & George, 2002; Przewłocki, 2017; George & Koob, 2017; Dydyk et al., 2021). The transition from voluntary use to compulsive drug-seeking is driven by profound neuroadaptations within the brain's reward, stress, and executive control circuits (Kosten & George, 2002; George & Koob, 2017; Roberts & Koob, 1997).

This chapter will provide a comprehensive examination of the biological basis of opioid intoxication. It will deconstruct the neuropharmacological mechanisms of action, from the molecular level of receptor signaling to the systems-level disruption of integrated neural circuits. We will explore the roles of key neurotransmitter systems, including the endogenous opioid, dopaminergic, noradrenergic, and glutamatergic pathways, in producing the hallmark symptoms of intoxication. Furthermore, this chapter will address the structural and functional brain changes associated with opioid exposure, the unique vulnerabilities presented during critical neurodevelopmental periods, and the molecular basis of phenomena such as tolerance, physical dependence, and opioid-induced hyperalgesia (OIH), which are inextricably linked to the state of intoxication in chronic users. Finally, we will review the biological mechanisms underlying current treatments and explore future directions in the field, aiming to provide a foundational understanding of a condition that remains a central challenge in modern medicine and public health.

## Neurobiological Systems

The profound effects of opioid intoxication are mediated through the coordinated action and subsequent disruption of several critical neurobiological systems. These substances hijack endogenous pathways that regulate pain, reward, mood, and autonomic function, leading to the characteristic constellation of symptoms observed clinically. A deep understanding of these systems is essential to comprehending both the acute effects of opioids and the long-term neuroadaptations that define dependence and addiction.

### Neurotransmitter Systems and Neuropharmacology

**The Endogenous Opioid System**
The human body possesses an innate system of opioid peptides, including endorphins, enkephalins, and dynorphins, which act as endogenous ligands for opioid receptors (Trachtenberg & Blum, 1987; Blum & Trachtenberg, 1988). This system is integral to modulating pain, stress responses, emotional regulation, and reward (Arbuck, 2022; Stein, 2021). Exogenous opioids, such as morphine and heroin, exert their effects by mimicking and overwhelming these natural peptides, binding with high affinity to the same receptors (Lambert, 2023; Trachtenberg & Blum, 1987).

There are three classical types of opioid receptors: mu (μ), delta (δ), and kappa (κ), all of which are G-protein coupled receptors (GPCRs) (Koch et al., 2003; Lambert, 2023). A fourth receptor, the nociceptin/orphanin FQ (NOP) receptor, is structurally related but functionally distinct (Lambert, 2023). The μ-opioid receptor (MOP) is the primary target for most clinically relevant and abused opioids and is responsible for their profound analgesic effects, as well as euphoria, respiratory depression, and physical dependence (Rowbotham et al., 2008; Lambert, 2023; Thakrar & Rastegar, 2025). Kappa receptor activation is associated with analgesia but can also produce dysphoria and hallucinations, while delta receptors are implicated in analgesia and mood regulation (Koch et al., 2003; Lambert, 2023).

The pharmacology of exogenous opioids is defined by their interaction with these receptors. **Full agonists**, such as morphine, heroin, fentanyl, and methadone, bind to and fully activate the μ-receptor, producing a maximal pharmacological response (Thakrar & Rastegar, 2025; Bhatt & Gill, 2016). **Partial agonists**, like buprenorphine, also activate the μ-receptor but produce a submaximal response, even at high doses; this "ceiling effect" makes buprenorphine a safer option regarding respiratory depression (Laks & Alford, 2024; Zoorob et al., 2018). **Antagonists**, such as naloxone and naltrexone, bind to the receptors but do not activate them, thereby blocking the effects of agonists (Thakrar & Rastegar, 2025; Kosten & George, 2002; Lipman, 1990). The interplay between these drug classes and the receptor subtypes dictates the clinical presentation of intoxication and informs therapeutic strategies for overdose and dependence.

**The Dopaminergic System**
The euphoric and reinforcing effects of opioids, which are central to their abuse potential, are primarily mediated through their interaction with the mesocorticolimbic dopamine system (Kosten & George, 2002; Beninger, 2018; George & Koob, 2017). This "reward pathway," originating in the ventral tegmental area (VTA) and projecting to the nucleus accumbens (NAc) and prefrontal cortex (PFC), is the common neural currency for reward and motivation (Wyatt, 1986; Bechara et al., 2019). Opioids do not act directly on dopamine neurons; instead, they bind to μ-receptors located on inhibitory gamma-aminobutyric acid (GABA) interneurons within the VTA (Corre, 2018; Kosten & George, 2002). This binding inhibits the GABAergic neurons, thereby "disinhibiting" the dopamine neurons and causing a surge of dopamine release in the NAc (Corre, 2018; Mameli, 2009). This dopamine surge is experienced as a "rush" or euphoria and powerfully reinforces the drug-taking behavior (Hansen, 2016; Kosten & George, 2002). Chronic opioid use leads to neuroadaptations in this system, contributing to the anhedonia and dysphoria seen in withdrawal (Kosten & George, 2002; George & Koob, 2017).

**The Noradrenergic System**
The locus coeruleus (LC), a brainstem nucleus, is the principal source of norepinephrine (NE) in the brain and plays a critical role in arousal, vigilance, and the autonomic stress response (Pergolizzi et al., 2020). The LC is densely populated with μ-opioid receptors. Acute opioid administration inhibits the firing of LC neurons, contributing to the sedative and analgesic effects of intoxication (Pergolizzi et al., 2020). However, with chronic exposure, LC neurons adapt by upregulating the cAMP signaling pathway to counteract this persistent inhibition (Koch et al., 2003). Upon abrupt cessation of opioids, the inhibitory influence is removed, and the adapted, now hyperexcitable LC neurons fire at an abnormally high rate (Pergolizzi et al., 2020). This massive release of NE throughout the brain and periphery is responsible for many of the severe autonomic symptoms of withdrawal, such as tachycardia, hypertension, sweating, anxiety, and agitation (Miller et al., 2016; Pergolizzi et al., 2020; Sarkar et al., 2023).

**The Glutamatergic System**
The excitatory neurotransmitter glutamate, acting primarily through the N-methyl-D-aspartate (NMDA) receptor, is fundamental to synaptic plasticity, learning, and memory (Trujillo, 2002). This system plays a crucial role in the neuroadaptations that underlie opioid tolerance and the phenomenon of opioid-induced hyperalgesia (OIH)—a paradoxical state where opioid exposure increases pain sensitivity (Mitra, 2018; Bekhit, 2010). Chronic opioid administration leads to an upregulation of the NMDA receptor system, which counteracts the inhibitory effects of opioids (Trujillo, 2002). This neuroplastic change contributes to tolerance, requiring higher doses to achieve the same effect (Bekhit, 2010; Trujillo, 2002). Furthermore, this enhanced glutamatergic activity is thought to be a key mechanism in OIH, where the nervous system becomes sensitized to pain (Mitra, 2018; Arbuck, 2022; Sochacki, 2025). The activation of NMDA receptors during intense noxious stimuli or with large opioid doses can lead to central sensitization, a state of hyperexcitability in the spinal cord and brain that contributes to chronic pain and hyperalgesia (Daccache et al., 2017; Deng et al., 2019).

## Genetic and Molecular Basis

The state of opioid intoxication and the subsequent risk of developing opioid use disorder are not uniform across individuals. A significant portion of this variability is attributable to genetic predispositions and the complex molecular adaptations that occur within neurons in response to opioid exposure. These factors influence everything from the initial subjective experience of the drug to the long-term trajectory of dependence.

### Heritability and Genetic Factors

Opioid use disorder is recognized as a condition with a strong genetic component, influencing an individual's vulnerability to transitioning from initial use to compulsive use (Przewłocki, 2017; Laks & Alford, 2024; George & Koob, 2017). Genetic factors may account for a substantial portion of the risk for developing opioid dependence (Law et al., 2009; Schuckit, 2016). This heritability is polygenic, involving multiple genes that regulate neurotransmitter systems, stress response, and neuroplasticity (Kosten & George, 2002; Przewłocki, 2017).

A key area of research involves polymorphisms in the genes encoding opioid receptors, particularly the μ-opioid receptor gene (*OPRM1*) (Lambert, 2023). Variations in this gene can alter receptor expression, binding affinity, and signaling efficiency, thereby modifying an individual's response to both endogenous and exogenous opioids (Nutt & Nestor, 2018). Such genetic differences may influence the intensity of euphoria, the degree of analgesia, and the severity of side effects, including respiratory depression, thereby shaping an individual's risk for continued use and dependence (Lambert, 2023). Beyond receptors, genetic variations in enzymes involved in opioid metabolism (e.g., cytochrome P450 enzymes) can affect drug clearance and bioavailability, further contributing to inter-individual differences in drug response and toxicity (Razaq et al., 2007; Laks & Alford, 2024). Genetic factors may also predispose individuals to certain personality traits, such as impulsivity or novelty-seeking, which are associated with a higher risk of substance use disorders (Voon et al., 2007; Kim et al., 2019).

### Cellular and Synaptic Mechanisms

The acute effects of opioid intoxication and the chronic adaptations of dependence are rooted in specific molecular events at the cellular and synaptic level. These mechanisms illustrate the brain's attempt to maintain homeostasis in the face of persistent pharmacological disruption.

**Receptor Signaling and Neuronal Inhibition**
Opioid receptors are G-protein coupled receptors (GPCRs) that, upon activation by an agonist, initiate an intracellular signaling cascade (Koch et al., 2003). The G-protein's α-subunit inhibits the enzyme adenylyl cyclase, leading to a decrease in the production of the second messenger cyclic AMP (cAMP) (Koch et al., 2003; Liu & JunHong, 2010). The βγ-subunit of the G-protein directly modulates ion channels, leading to the closing of voltage-gated calcium (Ca²⁺) channels and the opening of G-protein-coupled inwardly rectifying potassium (K⁺) channels (Koch et al., 2003). The reduced Ca²⁺ influx diminishes neurotransmitter release from the presynaptic terminal, while the increased K⁺ efflux hyperpolarizes the postsynaptic neuron, making it less excitable (Koch et al., 2003). This combined presynaptic and postsynaptic inhibition is the fundamental mechanism by which opioids produce analgesia, sedation, and respiratory depression (Lambert, 2023; Cook et al., 2019).

**Molecular Basis of Tolerance and Dependence**
Chronic exposure to opioid agonists triggers profound neuroadaptive changes, as the neuron attempts to counteract the persistent inhibitory signal. A key mechanism is the upregulation of the cAMP pathway (Koch et al., 2003; Noble & Roques, 2003). In response to chronic inhibition, the cell increases the synthesis of adenylyl cyclase and protein kinase A (PKA), leading to a state of cAMP pathway supersensitivity (Koch et al., 2003). This adaptation means that a higher dose of the opioid is required to achieve the same degree of cAMP inhibition, a cellular correlate of tolerance (Hansen, 2016; Koch et al., 2003).

This upregulated cAMP system also forms the basis of physical dependence (Wikler, 1980; Noble & Roques, 2003). When the opioid is abruptly withdrawn, its inhibitory influence is removed, and the supersensitive cAMP pathway becomes massively overactive, leading to a state of neuronal hyperexcitability that manifests as the somatic and affective symptoms of withdrawal (Kosten & George, 2002; Liu & JunHong, 2010; Pergolizzi et al., 2020). These changes are driven by alterations in gene expression mediated by transcription factors like the cAMP response element-binding protein (CREB) (Koch et al., 2003).

**Receptor Regulation and Plasticity**
In addition to signaling pathway adaptations, the opioid receptors themselves undergo regulation. Prolonged agonist exposure leads to receptor phosphorylation by G-protein-coupled receptor kinases (GRKs), which promotes the binding of β-arrestin proteins (Koch et al., 2003). β-arrestin binding uncouples the receptor from its G-protein, a process known as desensitization, and can target the receptor for removal from the cell surface via endocytosis (internalization) (Koch et al., 2003). Both desensitization and internalization contribute to the development of tolerance by reducing the number of functional receptors available to respond to the drug (Bekhit, 2010).

A more recently appreciated concept is **biased agonism**, or functional selectivity (Lambert, 2023). This principle posits that a single ligand can stabilize different receptor conformations, leading to preferential activation of certain downstream signaling pathways over others (e.g., G-protein signaling vs. β-arrestin signaling) (Mailman & Murthy, 2010; Lambert, 2023). This is clinically significant because different pathways may be responsible for different effects; for instance, G-protein signaling is thought to mediate analgesia, while β-arrestin pathways may be more involved in respiratory depression and tolerance (Lambert, 2023). This discovery has opened avenues for designing "biased agonists" that could selectively promote therapeutic effects while minimizing adverse ones.

## Brain Structure and Function

Opioid intoxication is fundamentally a disorder of brain function, arising from the drug's interaction with specific neural circuits. These interactions produce the acute behavioral and physiological changes characteristic of the intoxicated state, while chronic exposure can lead to lasting structural and functional alterations that underpin addiction.

### Brain Regions and Neural Circuits

The effects of opioids are not uniform across the brain but are concentrated in regions with high densities of opioid receptors. These regions form interconnected circuits that govern pain, reward, emotion, and autonomic control.

**The Mesolimbic Reward Pathway:** This circuit, comprising dopaminergic neurons projecting from the Ventral Tegmental Area (VTA) to the Nucleus Accumbens (NAc), is central to the rewarding and reinforcing effects of opioids (Kosten & George, 2002; George & Koob, 2017). As previously discussed, opioids disinhibit these dopamine neurons, leading to a surge of dopamine in the NAc that is experienced as euphoria (Corre, 2018; Mameli, 2009). This powerful reinforcement signal is a key driver for the initiation and maintenance of drug use (Bechara et al., 2019; Hansen, 2016).

**Brainstem Centers:** Several nuclei within the brainstem, including the pons and medulla, are critically involved in the life-threatening effects of opioid intoxication (Fareed et al., 2011). These regions contain respiratory centers that control the rhythm and depth of breathing. High densities of μ-opioid receptors in these areas make them exquisitely sensitive to the inhibitory effects of opioids, leading to profound respiratory depression, which is the primary cause of death in overdose (Jones et al., 2023; Dolinak, 2017; Williams & Erickson, 2000). The brainstem also contains the area postrema (chemoreceptor trigger zone), which mediates the nausea and vomiting frequently associated with opioid use (Olarte, 2008; Mercadante, 2019).

**Pain Modulatory Pathways:** The analgesic effects of opioids are mediated through actions at multiple levels of the nervous system. In the spinal cord, opioids inhibit the transmission of pain signals from the periphery to the brain (Stein, 1997). In the brainstem, they activate descending inhibitory pathways that further suppress nociceptive signaling in the spinal cord (Lambert, 2023). The thalamus, a major relay station for sensory information, is another key site of opioid analgesic action (Lambert, 2023).

**Limbic Structures:** The hippocampus and amygdala are crucial for the memory and emotional components of drug use (Kosten & George, 2002). The hippocampus is involved in forming memories that associate drug use with specific environmental cues, which can later trigger craving (DeJong, 1969). The amygdala processes the emotional valence of these experiences, linking the drug's effects to feelings of pleasure or, during withdrawal, to dysphoria and anxiety (Kosten & George, 2002). Opioid-induced cognitive effects, particularly memory impairment, are a common feature of both acute intoxication and chronic use (Dhingra et al., 2015; Su, 2007). A specific condition known as Opioid-Associated Amnestic Syndrome (OAS) has been described, characterized by acute anterograde amnesia and bilateral hippocampal edema on neuroimaging, often linked to fentanyl abuse (Walker et al., 2021; Kassir et al., 2021).

**Prefrontal Cortex (PFC):** The PFC is the seat of executive functions, including decision-making, impulse control, and judgment (George & Koob, 2017). This region is profoundly affected by chronic drug use, leading to a transition from controlled to compulsive drug-seeking behavior (Bechara et al., 2019). During acute intoxication, opioid effects on the PFC can contribute to impaired judgment and risky behaviors (Sarkar et al., 2023). In addiction, functional deficits in the PFC undermine an individual's ability to resist cravings and make choices aligned with long-term goals (Stewart et al., 2019).

### Neuroimaging Findings

While direct neuroimaging of acute opioid intoxication is less common outside of overdose scenarios, studies of chronic opioid users have provided invaluable insights into the lasting structural and functional changes in the brain. These alterations create the neurobiological context in which acute intoxication occurs and becomes progressively more problematic.

**Structural Imaging:** Magnetic Resonance Imaging (MRI) studies have consistently revealed structural brain changes in individuals with long-term opioid use (Laks & Alford, 2024; Kosten & George, 2002). These changes include reductions in gray matter volume in key regions such as the frontal cortex, anterior cingulate, and insula, areas critical for executive control and self-awareness (Howes et al., 2004; Stewart et al., 2019). White matter integrity is also compromised, with evidence of atrophy and reduced connectivity observed using techniques like Diffusion Tensor Imaging (DTI) (Slobodin & Odeh, 2015; Anghelescu et al., 2018). These structural deficits are thought to contribute to the cognitive impairments and poor decision-making characteristic of addiction (George & Koob, 2017). In severe overdose cases leading to hypoxia, neuroimaging can reveal widespread ischemic damage, with particular vulnerability noted in structures like the globus pallidus and hippocampus (Leal et al., 2022; Shprecher & Mehta, 2010).

**Functional Imaging:** Functional MRI (fMRI) and Positron Emission Tomography (PET) studies have demonstrated altered patterns of brain activity in individuals with OUD. During exposure to drug-related cues, there is heightened activation in reward-related regions like the NAc and amygdala, coupled with reduced activation in prefrontal control regions (Stewart et al., 2019). This pattern reflects a brain that is hypersensitive to drug cues but has a diminished capacity to regulate the resulting cravings and impulses (George & Koob, 2017). Functional imaging also shows that successful treatment interventions can lead to normalization of activity in these circuits, suggesting a potential for brain rehabilitation (Stewart et al., 2019; Kosten & George, 2002). These imaging techniques are also crucial in the emergency setting to exclude other causes of altered consciousness in a patient with suspected overdose, such as intracranial hemorrhage or stroke (Wijdicks, 2025; Sarkar et al., 2023).

## Developmental Neurobiology

The impact of opioids on the nervous system is not uniform across the lifespan. The developing brain, from the prenatal period through adolescence, exhibits unique vulnerabilities to the neurobiological effects of these substances. Exposure during these critical periods can disrupt normal developmental trajectories, leading to immediate and long-lasting neurological and behavioral consequences.

### Adolescence as a Vulnerable Period

Adolescence is a period of significant brain maturation, characterized by extensive synaptic pruning and myelination, particularly within the prefrontal cortex (PFC) and its connections to limbic structures (Hyytiä, 2015; Quartini et al., 2018). This ongoing development of circuits responsible for executive function, impulse control, and decision-making renders adolescents particularly vulnerable to the effects of psychoactive substances (McArdle & Angom, 2012; Winters & Ingwalson, 2022).

Exposure to opioids during this time can interfere with these normal neurodevelopmental processes (Hyytiä, 2015). The powerful rewarding effects of opioids can strongly shape adolescent learning and behavior, potentially leading to a more rapid progression from experimental use to addiction (Kosten & George, 2002). Furthermore, drug-induced alterations in dopamine and other neurotransmitter systems may disrupt the refinement of neural circuits, potentially leading to long-term deficits in cognitive control and an increased susceptibility to substance use disorders and other psychiatric conditions later in life (Quartini et al., 2018; Howes et al., 2004). The heightened impulsivity and risk-taking behavior characteristic of adolescence, combined with the impaired judgment caused by opioid intoxication, create a high-risk scenario for accidental overdose and other negative consequences (Sarkar et al., 2023; Winters & Ingwalson, 2022).

### Prenatal Exposure and Neonatal Abstinence Syndrome (NAS)

When a pregnant individual uses opioids, the drugs readily cross the placenta, exposing the developing fetus to their pharmacological effects (Ornoy, 2002). Chronic in utero exposure leads to the development of physical dependence in the fetus. Upon birth, the newborn is abruptly cut off from the maternal supply of the opioid, precipitating a withdrawal syndrome known as Neonatal Abstinence Syndrome (NAS) (Ko et al., 2017).

NAS is a multisystemic disorder characterized by a constellation of signs and symptoms reflecting CNS hyperexcitability and autonomic dysregulation (Nargarathan et al., 2019; Alba López et al., 2019). Neurological manifestations are prominent and include a high-pitched cry, irritability, tremors, increased muscle tone, and seizures (Ko et al., 2017; Ledesma Serrano, 2019). Gastrointestinal dysfunction, such as feeding difficulties, vomiting, and diarrhea, is also common, along with autonomic signs like fever, sweating, and tachypnea (Ko et al., 2017; Nargarathan et al., 2019). The clinical picture of NAS is a direct neurological consequence of the sudden cessation of opioid signaling in a nervous system that has adapted to their constant presence (Kosten & George, 2002).

Beyond the immediate crisis of NAS, prenatal opioid exposure can have long-term neurodevelopmental consequences. While the confounding effects of polysubstance use and adverse socioeconomic environments make it difficult to isolate the specific effects of opioids, studies suggest that exposed children are at higher risk for developmental delays, cognitive and learning problems, attention deficits, and behavioral issues (Ornoy, 2002; Lewis & Woods, 1994). These long-term effects may stem from opioid-induced disruptions of critical prenatal neurodevelopmental processes, including neuronal proliferation, migration, and differentiation (Ornoy, 2002).

## Treatment Mechanisms

The neurobiological understanding of opioid intoxication and dependence directly informs the pharmacological strategies used for its treatment. Interventions are designed to target specific components of the opioid system and related pathways, aiming to reverse life-threatening overdose, manage withdrawal, and support long-term recovery by mitigating cravings and preventing relapse.

### Reversal of Acute Intoxication and Overdose

The primary goal in managing acute opioid overdose is the rapid reversal of respiratory depression, the main cause of mortality (Jones et al., 2023; Dolinak, 2017).

**Naloxone:** The cornerstone of overdose treatment is the administration of naloxone, a pure, high-affinity competitive opioid antagonist (Jones et al., 2023; Williams & Erickson, 2000). Naloxone works by binding to μ-opioid receptors with greater affinity than most opioid agonists, thereby displacing them from the receptor and rapidly reversing their effects (Ostwal et al., 2017; Thakrar & Rastegar, 2025). This competitive antagonism restores respiratory drive, improves consciousness, and normalizes pupillary size (Jones et al., 2023; Sedlić, 2017). A critical pharmacological consideration is naloxone's relatively short duration of action (30-90 minutes) compared to many opioids, such as methadone or fentanyl (Fareed et al., 2011; Jones et al., 2023). This mismatch necessitates careful monitoring and often requires repeated doses or a continuous infusion of naloxone to prevent the patient from relapsing into respiratory depression as the antagonist is metabolized and the agonist re-engages the receptors (Thakrar & Rastegar, 2025; Fareed et al., 2011). In physically dependent individuals, naloxone can precipitate a severe, acute withdrawal syndrome (Bell, 1997; Williams & Erickson, 2000).

### Management of Dependence and Withdrawal

Pharmacotherapy for OUD is aimed at stabilizing the patient's neurobiology, alleviating withdrawal symptoms, and reducing the reinforcing effects of illicit opioid use.

**Opioid Agonist Therapy (OAT):** This is the most effective treatment for OUD (Schuckit, 2016; Zoorob et al., 2018).
*   **Methadone:** As a long-acting, full μ-opioid agonist, methadone occupies and activates opioid receptors, thereby preventing withdrawal symptoms and reducing cravings (Kosten & George, 2002; Laks & Alford, 2024). Its slow onset and long duration of action provide a stable level of opioid effect, which blocks the euphoric "rush" from short-acting opioids like heroin and helps to normalize the neurobiological disruptions caused by the chaotic cycle of intoxication and withdrawal (Kleber, 2007; Laks & Alford, 2024).
*   **Buprenorphine:** A high-affinity, partial μ-agonist, buprenorphine provides sufficient receptor stimulation to alleviate withdrawal and cravings but has a "ceiling effect" on respiratory depression, making it safer in overdose than full agonists (Laks & Alford, 2024; Zoorob et al., 2018). Its high affinity allows it to displace other opioids from the receptor, which can precipitate withdrawal if administered to a patient who has recently used a full agonist (Laks & Alford, 2024; Kleber, 2007). This property also allows it to block the effects of subsequent illicit opioid use.

**Opioid Antagonist Therapy:**
*   **Naltrexone:** A long-acting opioid antagonist, naltrexone blocks the euphoric and reinforcing effects of opioids by occupying the μ-receptor without activating it (Kosten & George, 2002; Thakrar & Rastegar, 2025). This blockade can help extinguish the learned association between drug use and reward. A major clinical challenge is that patients must be fully detoxified from opioids before starting naltrexone, as it will otherwise precipitate severe withdrawal (Laks & Alford, 2024; Kleber, 2007).

**Non-Opioid Symptomatic Treatment:**
*   **Alpha-2 Adrenergic Agonists (Clonidine and Lofexidine):** These medications are used to manage the symptoms of acute opioid withdrawal (Thakrar & Rastegar, 2025; Rastegar, 2020). They act on presynaptic α2-receptors in the locus coeruleus and other autonomic centers, reducing the sympathetic hyperactivity that drives many withdrawal symptoms like tachycardia, sweating, anxiety, and restlessness (Pergolizzi et al., 2020; Salazar et al., 2024). They do not, however, effectively treat other withdrawal symptoms like insomnia, muscle aches, or craving (Kosten & George, 2002).

**Opioid Rotation:** In clinical pain management, the practice of opioid rotation—switching from one opioid to another—can be an effective strategy to manage intolerable side effects or poor analgesic response (Olarte, 2008; Mercadante, 1999). This phenomenon is explained by incomplete cross-tolerance between different opioids and variations in individual receptor binding profiles and metabolite accumulation (Mercadante, 1999; Pawasauskas, 2015). This strategy leverages the neurobiological heterogeneity of opioid responses to optimize the therapeutic window.

## Future Directions

While our understanding of the neurobiology of opioid intoxication has advanced significantly, the ongoing opioid crisis underscores the urgent need for continued research and innovation. Future efforts are focused on developing safer analgesics, refining treatments for OUD, and personalizing interventions based on individual neurobiology.

**Novel Pharmacotherapies for Pain and Addiction:**
A primary goal of modern pharmacology is to dissociate the powerful analgesic properties of opioids from their life-threatening side effects and abuse potential. One of the most promising avenues is the development of **biased agonists** (Lambert, 2023). Based on the principle of functional selectivity, these molecules are designed to preferentially activate the G-protein signaling pathways associated with analgesia, while avoiding the recruitment of β-arrestin pathways linked to respiratory depression, tolerance, and reward (Mailman & Murthy, 2010; Lambert, 2023). Such compounds could theoretically provide potent pain relief with a significantly improved safety profile.

Another strategy involves **positive allosteric modulators (PAMs)** of opioid receptors (Lambert, 2023). Unlike direct agonists, PAMs do not activate the receptor themselves but instead bind to a different site on the receptor to enhance the effect of endogenous opioid peptides (endorphins). This approach could amplify the body's natural pain-relief mechanisms, potentially offering analgesia with fewer side effects and lower abuse liability (Lambert, 2023).

**Targeting Neuroinflammation:**
Emerging evidence suggests that chronic opioid use induces a state of persistent neuroinflammation, involving the activation of glial cells (microglia and astrocytes) in the CNS (Nidode et al., 2024). This inflammatory response is increasingly implicated in the development of opioid tolerance, OIH, and the negative affective state of withdrawal (Nidode et al., 2024). Consequently, targeting these neuroinflammatory pathways with novel anti-inflammatory agents or glial modulators represents a new therapeutic frontier. Such treatments could potentially mitigate the adverse neuroadaptations of chronic opioid use, restore analgesic efficacy, and alleviate withdrawal symptoms.

**Advanced Neuromodulation Techniques:**
Beyond pharmacology, brain stimulation techniques are being explored as potential treatments for addiction. While the evidence base is still nascent, methods such as deep brain stimulation (DBS) and transcranial magnetic stimulation (TMS) are being investigated for their ability to modulate activity in the neural circuits disrupted by chronic drug use, particularly the reward and executive control pathways (Poewe et al., 2020; Stewart et al., 2019). The goal of these interventions is to re-normalize circuit function, reduce craving, and improve impulse control, thereby aiding in relapse prevention (Stewart et al., 2019).

**Biomarkers and Personalized Medicine:**
The future of addiction treatment lies in personalized medicine. A significant challenge is the identification of robust **biomarkers**—whether genetic, neuroimaging, or biochemical—that can predict an individual's risk of developing OUD, their likely response to specific treatments, or their vulnerability to relapse (George & Koob, 2017). Identifying genetic polymorphisms that confer risk (Przewłocki, 2017) or functional brain patterns that predict treatment success could allow clinicians to tailor interventions to the individual patient, moving beyond a one-size-fits-all approach and optimizing outcomes (Stewart et al., 2019). This would enable more precise application of existing therapies and guide the development of targeted new ones.

## Conclusion

Opioid intoxication represents a complex and multifaceted neurobiological phenomenon with profound clinical and societal implications. Its manifestations, ranging from the sought-after effects of analgesia and euphoria to the life-threatening consequences of respiratory depression and coma, are all rooted in the interaction of opioid compounds with a highly conserved system of receptors and endogenous peptides (Lambert, 2023; Thakrar & Rastegar, 2025). The acute state is driven primarily by the potent inhibitory actions of opioids, particularly at the μ-opioid receptor, across critical brain circuits that regulate pain, reward, arousal, and autonomic function (Kosten & George, 2002; Fareed et al., 2011).

The core of the opioid's addictive potential lies in its ability to powerfully activate the mesolimbic dopamine system, creating a reinforcing signal that can override normal motivational drives (George & Koob, 2017; Beninger, 2018). However, the biology of opioid use extends far beyond this acute reward. Chronic exposure forces a cascade of neuroadaptations in the dopaminergic, noradrenergic, and glutamatergic systems, leading to the debilitating states of tolerance, physical dependence, and opioid-induced hyperalgesia (Kosten & George, 2002; Pergolizzi et al., 2020; Trujillo, 2002). These allostatic changes transform the brain, shifting the motivation for drug use from positive reinforcement (seeking pleasure) to negative reinforcement (avoiding the dysphoria and physical distress of withdrawal) (George & Koob, 2017; Bechara et al., 2019).

This deep understanding of the underlying neurobiology provides a rational basis for the entire spectrum of clinical interventions. The emergency reversal of overdose with competitive antagonists like naloxone is a direct application of receptor pharmacology (Jones et al., 2023). Similarly, long-term management of OUD with agonist (methadone) or partial agonist (buprenorphine) therapies is designed to stabilize the dysregulated opioid system, while antagonist therapy (naltrexone) aims to block the reinforcing effects of the drug (Laks & Alford, 2024; Kosten & George, 2002).

Despite these advances, significant challenges remain. The heterogeneity of individual responses, influenced by genetic and environmental factors, complicates treatment (Przewłocki, 2017). The continued evolution of the illicit drug market, particularly the proliferation of highly potent synthetic opioids like fentanyl, presents new and urgent dangers (Lutfy, 2020). Future progress will depend on leveraging our growing molecular knowledge to develop novel therapeutics, such as biased agonists and allosteric modulators, that can separate therapeutic efficacy from adverse effects (Lambert, 2023). Furthermore, a continued focus on the neurodevelopmental impact of opioids and the role of neuroinflammation will be critical. Ultimately, a comprehensive, biologically informed approach is essential to mitigate the harms of opioid intoxication and offer more effective, personalized pathways to recovery for those affected by opioid use disorder.

## References

1. Abdalá, L., & Arturo (2019). Abuso psicológico (AP).
2. Abdelsayed, S., Acevedo, R., & Clemow, L. (2017). Is sleep deprivation associated with behavioral changes in children and adolescents?. Evidence-Based Practice. https://doi.org/10.1097/01.ebp.0000541629.93211.cb
3. AbdulRahman, I., Yaqoob, Ú., & Bhatti, T. A. (2018). Sleep Disorders Caused by Depression. Clinical Depression. https://doi.org/10.4172/2572-0791.1000131
4. Acuña, J. P. (2019). RIESGO DE ADICCIÓN A ANALGÉSICOS OPIOIDES EN EL TRATAMIENTO DE DOLOR CRÓNICO NO ONCOLÓGICO. Revista Médica Clínica Las Condes. https://doi.org/10.1016/j.rmclc.2019.10.004
5. Acuña, J. P., Álvarez, J. P., & Cánepa, P. (2017). SANANDO AL SANADOR. Revista Médica Clínica Las Condes. https://doi.org/10.1016/j.rmclc.2017.08.009
6. Aghababaeian, H., & Ahvazi, L. A. (2018). Isn’t it Time to Use Opioid Drugs in Emergency Medical Services?. DOAJ (DOAJ: Directory of Open Access Journals).
7. Ahemad, M., Ahmad, P. M. F., & Shafaat, M. (2018). Effect of Dalak (Massage) in the Management of Sahar (Insomnia). https://doi.org/10.37591/rrjoush.v5i2.130
8. Ahmed, S., & Paul, S. P. (2019). A Diagnostic Conundrum: Acute Intermittent Porphyria Coexisting with Lumbar Prolapsed Intervertebral Disc. Journal of College of Physicians And Surgeons Pakistan. https://doi.org/10.29271/jcpsp.2019.12.1236
9. Akram, A. S., Sarwar, R., Zafar, M. F., Umair, M., Ullah, I., & Nazir, A. (2023). First oral treatment zuranolone’s FDA approval and its impact on postpartum depression: a new hope – a correspondence. International Journal of Surgery Global Health. https://doi.org/10.1097/gh9.0000000000000345
10. Albalawi, R., Alsahli, H., Almutairi, N. B., & Alhashemi, M. (2024). Acute psychosis and behavioural changes with seizure-like hyperactive psychomotor activity secondary to isotretinoin initiation in a healthy young male: case report. Annals of Medicine and Surgery. https://doi.org/10.1097/ms9.0000000000001726
11. Alfarossi, O. L., & Hutasoit, H. B. K. (2020). Gejala Psikotik pada Pasien dengan Epilepsi Tidak Terkontrol. Jurnal Medula.
12. Alici, Y., & Breitbart, W. (2021). Delirium. CRC Press eBooks. https://doi.org/10.1201/9780429275524-47
13. Alromail, N. M. A., Halawani, M. S., & Malawi, I. A. (2017). Emergency Management of Stroke. The Egyptian Journal of Hospital Medicine. https://doi.org/10.12816/0042257
14. Alvarez, M. R., García, R. G., & Silva, F. A. (2010). Cefalea por uso excesivo de medicamentos: implicaciones clínicas y terapéuticas. Acta neurológica colombiana.
15. Ambikar, D., Melese, E., & Patil, M. J. (2018). Influence of Unani polyherbal formulation on learning and memory retention in mice. Deleted Journal. https://doi.org/10.29090/psa.2018.03.174
16. Amorim, M. J., Maurício, J., & Brandão, D. (2019). WHEN THE DISEASE ARISES FROM THE TREATMENT: CORTICOSTEROID-INDUCED PSYCHOSIS A CASE REPORT AND BRIEF LITERATURE REVIEW. https://doi.org/10.26226/morressier.5d1a037b57558b317a140b63
17. Amsterdam, J. V., Pierce, M., & Brink, W. V. D. (2023). Predictors and motives of polydrug use in opioid users. A narrative review. Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0000000000000875
18. Anand, K., Willson, D. F., Berger, J., Harrison, R., Meert, K. L., Zimmerman, J. J., Carcillo, J. A., Newth, C. J. L., Prodhan, P., Dean, J. M., & Nicholson, C. (2010). Tolerance and Withdrawal From Prolonged Opioid Use in Critically Ill Children. PEDIATRICS. https://doi.org/10.1542/peds.2009-0489
19. Anani, S., Goldhaber, G., Wasserstrum, Y., Dagan, A., & Segal, G. (2018). The ‘SILENT Alarm’: When History Taking Reveals a Potentially Fatal Toxicity. European Journal of Case Reports in Internal Medicine. https://doi.org/10.12890/2018_000843
20. Anghelescu, A., Magdoiu, A. M., Chirilă, I., Verișezan, O., Opincariu, I., Mureșanu, D. F., & Blesneag, A. (2018). None. Romanian Journal of Neurology. https://doi.org/10.37897/rjn.2018.s
21. Anghelescu, A., Magdoiu, A. M., Chirilă, I., Verișezan, O., Opincariu, I., Mureșanu, D. F., & Blesneag, A. (2018). ORAL PRESENTATION – ABSTRACTS. Romanian Journal of Neurology. https://doi.org/10.37897/rjn.2018.s.1
22. Anis, A., Noor, S., & Shakeel, A. (2025). Attention deficit hyperactivity disorder: a misdiagnosed disorder. International Journal of Scientific Reports. https://doi.org/10.18203/issn.2454-2156.intjscirep20250752
23. Aptikieva, L. (2020). PSYCHOLOGICAL VIOLENCE CONSEQUENCES FOR DIFFERENT AGE CATEGORIES. Vestnik Orenburgskogo gosudarstvennogo universiteta. https://doi.org/10.25198/1814-6457-224-6
24. Aquina, C. T., Marques‐Baptista, A., Bridgeman, P., & Merlin, M. A. (2009). OxyContin® Abuse and Overdose. Postgraduate Medicine. https://doi.org/10.3810/pgm.2009.03.1988
25. Arbuck, D. M. (2022). Neurotransmitter-based diagnosis and treatment: A hypothesis (Part 2). Current psychiatry. https://doi.org/10.12788/cp.0253
26. Arendt, M., Rosenberg, R., Fjordback, L., Brandholdt, J., Foldager, L., Sher, L., & Munk-Jørgensen, P. (2007). Testing the self-medication hypothesis of depression and aggression in cannabis dependent subjects. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2007.01.601
27. Arenson, C., Busby‐Whitehead, J., Brummel‐Smith, K., O’Brien, J. G., Palmer, M. H., & Reichel, W. (2010). Evaluation and Management of Dementia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511575952.017
28. Arpacı, A. H., Koç, A., Gürkan, Ö. E., Tosun, C., & Işık, B. (2017). Emergence Agitation or Excited Delirium. Gazi Medical Journal.
29. Asadi, S. (2023). The Role of Bio- Psychological Factors in Sleep Anxiety and Hypomania Disorder. https://doi.org/10.31579/2835-2882/016
30. Asadi‐Pooya, A. A., & Sperling, M. R. (2022). Clinically Important Drug Interactions with Antiseizure Medications. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197541210.003.0006
31. Aschenbrenner, D. S. (2015). A Rare Brain Infection with Multiple Sclerosis Dug. AJN American Journal of Nursing. https://doi.org/10.1097/01.naj.0000461811.72720.3a
32. Autor, J. L. M. C., & Principal, C. M. A. C. O. T. (2018). Demencia tipo Alzheimer vs pseudo demencia por depresión. Estudio neuropsicológico de un caso. XII CONGRESO DE POSGRADO EN PSICOLOGÍA | UNAM | 2018.
33. Ayala, L., Gómez‐Revuelta, M., Requena, C. M., Acilu, E. S. D. A. G. D., Olivares, O. P., Ruíz, M. J., Morales, N. N., Martin, M., Zufiaurre, M. L., Hernández, B., Itoiz, A. A., Peña, M., & González‐Pinto, A. (2017). Clozapine: Since the very beginning?. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.1402
34. Ayas, Ş., Öztürk, K., Gençeli, M., & Çaksen, H. (2019). Phenytoin Induced Anaphylaxis: a Case Report Fenitoin İlişkili Anaflaksi: Olgu Sunumu. Pediatric Practice and Research.
35. Aytaş, Ö., & Yalvaç, H. D. (2015). Modafinil-Induced Psychosis: A Case Report. Nöro Psikiyatri Arşivi. https://doi.org/10.5152/npa.2015.7160
36. Ayşe, H., Hakkı, ©., Arpacı, A. H., Koç, A., Gürkan, Ö. E., Tosun, C., & Işık, B. (2017). Emergence Agitation or Excited Delirium?. Gazi Medical Journal. https://doi.org/10.12996/gmj.2017.45
37. Baat, C. D. (2017). Medicaments and oral healthcare 4. Pharmacotherapy in (frail and care dependent) older people. Nederlands Tijdschrift voor Tandheelkunde. https://doi.org/10.5177/ntvt.2017.05.16244
38. Baek, J. H., Han, S., & Lee, S. (2015). Restless Leg Syndrome Induced by an Acute Withdrawal of Oxycodone. Sleep Medicine Research. https://doi.org/10.17241/smr.2015.6.2.84
39. Bahro, M., Missler, G., & Strnad, J. (1999). [Diagnosis and therapy of alcohol-withdrawal symptoms in the elderly: a case report].. PubMed.
40. Bains, N., Abdijadid, S., & Miller, J. (2021). Major Depressive Disorder (Nursing).
41. Bajabir, D., Albishri, A., Shaheen, H. A., Albalawi, A., Alshikhi, A., Alkhan, S., Almulhim, N., Alsaileek, Y., Alotaibi, M., Almuhanna, M., & Namar, R. A. (2022). Common Conditions Associated with Long Term Opioid Usage. Journal of Healthcare Sciences. https://doi.org/10.52533/johs.2022.21215
42. Balvir, K. S., Dhanvij, B., Telrandhe, S., & Wajgi, R. D. (2021). A Case Report on Management of Subdural Hematoma. NVEO - NATURAL VOLATILES & ESSENTIAL OILS Journal | NVEO.
43. Bansal, R., & Sheldon, S. H. (2008). Parasomnias in Childhood. CRC Press eBooks. https://doi.org/10.3109/9781420048087-26
44. Barbosa, G. (2017). Preservação das funções executivas em ratos expostos ao Status Epilepticus neonatal.
45. Barkin, R. L. (2007). Zolpidem Extended-Release: A Single Insomnia Treatment Option for Sleep Induction and Sleep Maintenance Symptoms. American Journal of Therapeutics. https://doi.org/10.1097/mjt.0b013e31804c7292
46. Barrios, M. D. M., & Escobar, L. E. Z. (2018). Disartria por el uso del diazepam en adultos mayores. Revista cubana de farmacia.
47. Batinić, B., Duišin, D., & Vukosavljevic-Gvozden, T. (2017). Neurobiological bases for impulsive and compulsive behaviour: Implications for pharmacological and psychological interventions. Engrami. https://doi.org/10.5937/engrami1701017b
48. Baweja, R., Sedky, K., & Lippmann, S. (2010). Clozapine associated delirium. Eastern Journal Of Medicine.
49. Bechara, A., Berridge, K., Bickel, W. K., Morón, J. A., Williams, S. B., & Stein, J. S. (2019). A Neurobehavioral Approach to Addiction: Implications for the Opioid Epidemic and the Psychology of Addiction. Psychological Science in the Public Interest. https://doi.org/10.1177/1529100619860513
50. Becker, M. A., Weinberger, T. E., & Ocker, L. J. (2022). Mood Disorders. CRC Press eBooks. https://doi.org/10.1201/9781003099062-21
51. Beghi, E., Carpio, A., Forsgren, L., Hesdorffer, D. C., Malmgren, K., Sander, J. W., Tomson, T., & Hauser, W. A. (2009). Recommendation for a definition of acute symptomatic seizure. Epilepsia. https://doi.org/10.1111/j.1528-1167.2009.02285.x
52. Bekhit, M. H. (2010). Opioid-Induced Hyperalgesia and Tolerance. American Journal of Therapeutics. https://doi.org/10.1097/mjt.0b013e3181ed83a0
53. Belli, H., Akbudak, M., Ural, C., & Kulacaoğlu, F. (2012). Solitary lesion in ponto-mesencephalic area related secondary mania: a case report.. PubMed.
54. Belmaker, R. H. (2004). Bipolar Disorder. New England Journal of Medicine. https://doi.org/10.1056/nejmra035354
55. Beninger, R. J. (2018). Life's rewards. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198824091.001.0001
56. Benítez, J. T., Meyer, E. D. D., & Fariña, E. D. (2019). Acute glaucoma and myopia induced by the use of topiramate. Anales de la Facultad de Ciencias Médicas (Asunción). https://doi.org/10.18004/anales/2019.052(02)35-038
57. Berg, J., Liempt, S. V., & Verwijk, E. (2019). Differentiële diagnostiek en behandeling van insomnie bij ouderen.
58. Bersani, F. S., Prevete, E., & Vicinanza, R. (2024). Schizophrenia and Other Late-Life Psychoses. Geriatric medicine. https://doi.org/10.1007/978-3-030-74720-6_87
59. Bertodo, T. D. S., Gross, M. S., & Maldaner, E. B. (2018). TRANSTORNOS BIPOLAR E DEPRESSIVO: UMA REVISÃO DOS ASPECTOS CONCEITUAIS.
60. Bhatt, A., & Gill, A. (2016). Opiate addiction - current trends and treatment options. International Journal of Research in Medical Sciences. https://doi.org/10.18203/2320-6012.ijrms20161911
61. Bhattacharya, S., Bashar, M., Srivastava, A., & Singh, A. (2019). NOMOPHOBIA: NO MObile PHone PhoBIA. Journal of Family Medicine and Primary Care. https://doi.org/10.4103/jfmpc.jfmpc_71_19
62. Bibi, E. S. D. M. (2021). AN OVERVIEW OF POST WAR SOCIAL PROBLEMS IN SYRIA. Pakistan Journal of International Affairs. https://doi.org/10.52337/pjia.v2i2.63
63. Bidaki, R., Yassini, S. M., & Anari, P. Y. (2016). Bizarre Delusions Follow Dopaminergic Therapy in Parkinson Disease: Challenge in Diagnosis and Treatment.
64. Bigio, M. R. D. (2021). Neuronal Death. Cambridge University Press eBooks. https://doi.org/10.1017/9781316671863.030
65. Bindu, P. S., Nagappa, M., Bharath, R. D., & Taly, A. B. (2017). Isolated Sulfite Oxidase Deficiency.
66. Bithal, P. K., & Chavali, S. (2021). Paroxysmal Sympathetic Hyperactivity: Ignoring the Presence of an Elephant in the Room. Journal of Neuroanaesthesiology and Critical Care. https://doi.org/10.1055/s-0041-1740206
67. Bitnun, A., & Richardson, S. E. (2015). Childhood Encephalitis in Canada in 2015. Canadian Journal of Infectious Diseases and Medical Microbiology. https://doi.org/10.1155/2015/947602
68. Blankenburg, M. (2016). Symptomkontrolle bei Lebenslimitierenden Neuropädiatrischen Krankheitsbildern. Neuropediatrics. https://doi.org/10.1055/s-0036-1583744
69. Blinick, R., Chaya, N., Zalta, B., Haramati, L. B., & Shmukler, A. (2020). Cracking the Opium Den. Journal of Thoracic Imaging. https://doi.org/10.1097/rti.0000000000000488
70. Blum, K., & Trachtenberg, M. C. (1988). Alcoholism: Scientific Basis of a Neuropsychogenetic Disease. International Journal of the Addictions. https://doi.org/10.3109/10826088809058839
71. Borie, Y. A., Tamiso, A., Gutema, K., Jisso, M., Deribe, B., Fikre, R., Defar, S., Ayalew, M., & Abera, W. (2024). Psychological distress and its associated factors among people with specific chronic conditions (diabetes and/or hypertension) in the Sidama region of southern Ethiopia: A cross-sectional study. PLoS ONE. https://doi.org/10.1371/journal.pone.0303196
72. Borovac, A. (2018). Zdravstvena njega bolesnika - ovisnika o psihoaktivnim tvarima.
73. Bradic, L., Lokmić-Pekić, I., & Dzevad, B. (2018). Psychiatric comorbidity in patients with posttraumatic stress disorder and enduring personality change after catastrophic experience. https://doi.org/10.26226/morressier.5b68175cb56e9b005965c22b
74. Breuer, L., Kasper, B. S., Schwarze, B., Gschossmann, J. M., Kornhuber, J., & Müller, H. (2015). “Herbal seizures” – atypical symptoms after ibogaine intoxication: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/s13256-015-0731-4
75. Brignole, M., Alboni, P., Benditt, D. G., Bergfeldt, L., Blanc, J., Thomsen, P. E. B., Dijk, J. G. V., Fitzpatrick, A., Hohnloser, S. H., Janousek, J., Kapoor, W. N., Kenny, R. A., Kułakowski, P., Masotti, G., Moyá, A., Raviele, A., Sutton, R., Theodorakis, G., Ungar, A., & Wieling, W. (2004). Guidelines on Management (diagnosis and treatment) of syncope ? update 2004. EP Europace. https://doi.org/10.1016/j.eupc.2004.08.008
76. Brito, A. D. S. (2015). Alcoolismo associado a transtornos mentais..
77. Brody, D. L. (2019). How Do You Make the Diagnosis of Concussion?. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190054793.003.0003
78. Brody, D. L. (2019). Psychosis. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190054793.003.0026
79. Broniarczyk-Czarniak, M., Sowińska, K., Białas, J., & Talarowska, M. (2019). Ciężka depresja z nasilonymi zaburzeniami funkcji poznawczych czy otępienie.
80. Brutto, Ó. H. D., Rumbea, D. A., & Recalde, B. Y. (2022). Bilateral necrosis of the globus pallidus after binge-drinking.. Revista Ecuatoriana de Neurologia. https://doi.org/10.46997/revecuatneurol31100105
81. Bukhari, S. N. A. (2022). Consequences of Antipsychotic Medications on Mental Health. Current Drug Safety. https://doi.org/10.2174/1574886317666220216101106
82. Campos, S. A., & Kerik-Rotenberg, N. E. (2017). Amaurosis bilateral por consumo de solventes: a propósito de un caso.
83. Capitani, E. M. D. (2009). Diagnóstico e tratamento da intoxicação por chumbo em crianças e adultos. Medicina (Ribeirão Preto). https://doi.org/10.11606/issn.2176-7262.v42i3p319-329
84. Caplan, L. R., & Aggarwal, A. (2022). Stroke-Related Terms. Cambridge University Press eBooks. https://doi.org/10.1017/9781009030854.044
85. Carr, B. I., Akkız, H., Guerra, V., Üsküdar, O., Kuran, S., Karaoğullarından, Ü., Tokmak, S., Ballı, T., Ülkü, A., Akçam, T., Delik, A., Benli, B. A., Doran, F., Yalçın, K., Altntaş, E., Özakyol, A., Yücesoy, M., Bahçeci, H. İ., Polat, K. Y., ... Tokat, Y. (2018). The patient burden of opioidinduced bowel dysfunction. Clinical Practice. https://doi.org/10.4172/clinical-practice.1000409
86. Carrera, M. A. V., Correa, S. M. V., Prado, M. M. C., & Granados, K. P. M. (2019). Manejo de intoxicación por opioides. RECIMUNDO. https://doi.org/10.26820/recimundo/3.(4).diciembre.2019.494-510
87. Carvajal-Castrillón, J., Aguirre, L. G., & Restrepo, F. L. (2009). AGNOSIA VISUOESPACIAL PROGRESIVA: UN CASO DE ATROFIA CORTICAL POSTERIOR. (Progressive visuospatial agnosia. a posterior cortical atrophy case.). CES Psicología.
88. Cassano, G. B., Toni, C., Petracca, A., Deltito, J., Benkert, O., Curtis, G., Hippius, H., Maier, W., Shera, D., & Klerman, G. L. (1994). Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology. https://doi.org/10.1016/0924-977x(94)90314-x
89. Catalano, G., Catalano, M. C., & Rodríguez, R. (1997). Dystonia Associated With Crack Cocaine Use. Southern Medical Journal. https://doi.org/10.1097/00007611-199710000-00017
90. Ce, B. (1997). Medical Complications of Drug Abuse. Routledge eBooks. https://doi.org/10.1201/9781420048292-8
91. Ceravolo, F., Sestito, S., Falvo, F., Salpietro, V., Polizzi, A., Ruggieri, M., Bruno, M., & Concolino, D. (2016). Neurological Involvement in Inherited Metabolic Diseases: An Overview. Journal of Pediatric Biochemistry. https://doi.org/10.1055/s-0036-1582235
92. Cerón-Apipilhuasco, A., Loría-Castellanos, J., & Gómez-Bañuelos, L. V. (2023). Intoxicaciones delictivas. Anales Médicos de la Asociación Médica del Centro Médico ABC. https://doi.org/10.24875/amh.m23000027
93. Chan, A. S. L., Phillips, C. L., & Cistulli, P. A. (2009). Obstructive sleep apnoea – an update. Internal Medicine Journal. https://doi.org/10.1111/j.1445-5994.2009.02069.x
94. Chang, Y., Han, I.-W., Na, H. R., & Kim, S.-Y. (2010). Encephalitis Lethargica With Catatonia. Journal of the Korean Neurological Association.
95. Chang, Y.-S., Anderson, N., Long, K., Murphy, C., McMahan, V., Rodda, L. N., Kral, A. H., & Coffin, P. O. (2025). Refining cause of death attribution among opioid, opioid‐stimulant and stimulant acute toxicity deaths. Addiction. https://doi.org/10.1111/add.70190
96. Chartrand, M. S. (2018). Awareness alert: adverse effects of hearing loss on mental and physical health. Journal of Otolaryngology-ENT Research. https://doi.org/10.15406/joentr.2018.10.00331
97. Chaudhary, M. A., & Rabheru, K. (2009). Síntomas paranoides en pacientes ancianos. RET: revista de toxicomanías.
98. Chauhan, R., Bhunal, S., Gupta, D., Kumar, R., & Sharma, T. (2020). TO STUDY CLINICAL PROFILE OF ACUTE CONFUSIONAL STATE IN A TERTIARY CARE HOSPITAL IN A HILLY AREA.. International Journal of Scientific Research. https://doi.org/10.36106/ijsr/0915904
99. Cheatle, M. D., & Webster, L. R. (2015). Opioid Therapy and Sleep Disorders: Risks and Mitigation Strategies. Pain Medicine. https://doi.org/10.1111/pme.12910
100. Chen, D., & LaFrance, W. C. (2018). Epilepsy and Seizures. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615372423.sy10
101. Cherian, K., Shinozuka, K., Tabaac, B. J., Arenas, A., Beutler, B. D., Evans, V. D., Fasano, C., & Muir, O. S. (2024). Psychedelic Therapy: A Primer for Primary Care Clinicians—Ibogaine. American Journal of Therapeutics. https://doi.org/10.1097/mjt.0000000000001723
102. Chowdhry, V., & Mohanty, B. (2016). Levofloxacin: a rarely suspected cause of delirium. Ain-Shams Journal of Anaesthesiology. https://doi.org/10.4103/1687-7934.189093
103. Chowdhury, T., Roy, P. D., & Chowdhury, H. I. (2021). Delusion in Parkinson’s disease: A Symptom or an Adverse Effect of Dopamine Agonist – A Case Report.
104. Chumpitazi, C. E. (2018). Minor Adverse Events. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190659110.003.0022
105. Clark, M., & McKinlay, J. (2009). Coma, Confusion, and Agitation in Intensive Care. Competency-based critical care. https://doi.org/10.1007/978-1-84882-070-8_11
106. Coelho, L. R. P., Batista, L. R., Silva, A. C. B., Ramos, A. C. R., Fagundes, L. M., Barros, B. E., Belfort, R. L. D. A., Vieira, M. R. V., Cavalcanti, A. T. L., & Silva, R. R. C. (2024). Diferenciação diagnóstica de crises neurológicas: Epilepsia, Síncope, Crises Psicogênicas, Enxaqueca e Narcolepsia. Europub Journal of Health Research. https://doi.org/10.54747/ejhrv8n2-008
107. Cole, M. G., & McCusker, J. (2009). Improving the outcomes of delirium in older hospital inpatients. International Psychogeriatrics. https://doi.org/10.1017/s1041610209008989
108. Conde, I. L., Fernández‐Montalvo, J., Ustárroz, J. T., González, N. L., & López‐Goñi, J. J. (2010). Rendimiento neuropsicológico en la adicción a la cocaína: una revisión crítica. Revista de Neurología. https://doi.org/10.33588/rn.5107.2010395
109. Conway, K. P., Montoya, I. D., & Compton, W. M. (2007). Lifetime Psychiatric Comorbidity of Illicit Drug Use Disorders. The Psychiatric times.
110. Cook, B. M., Geiger, K., & Barra, M. E. (2019). Opioids for Anesthesia and Postoperative Pain Control. https://doi.org/10.2310/anes.18224
111. Coronado, L. M. Q., Florez, D. A. C., & Tarazona, M. C. L. (2017). Prevalencia depresión en estudiantes universitarios Bucaramanga 2017.
112. Corre, J. (2018). Disinhibition of ventral tegmental area dopamine neurons projecting to the nucleus accumbens drives heroin reinforcement. https://doi.org/10.13097/archive-ouverte/unige:106828
113. Crișan, C. A. (2018). Lack of Insight in Bipolar Disorder: The Impact on Treatment Adherence, Adverse Clinical Outcomes and Quality of Life. InTech eBooks. https://doi.org/10.5772/intechopen.76286
114. Cruz, M. C. D., Camargo, R. P. D., Cruz, L. C. D., Schiefelbein, N., Cruz, D. M. D., & Cruz, M. C. C. D. (2020). Migrânea: revisão de literatura. ARCHIVES OF HEALTH INVESTIGATION. https://doi.org/10.21270/archi.v10i2.4670
115. Cruz, V. E. R., Palacios, L. P. T., Adriano, M. P. C., Lozada, E. M. V., Quingatuña, D. E. E., Reyes, E. P. B., Sailema, P. I. Y., Inca, J. I. S., & Ruiz, G. B. F. (2020). Avances en el manejo del delirium en los pacientes geriátricos. AVFT – Archivos Venezolanos de Farmacología y Terapéutica. https://doi.org/10.5281/zenodo.4058882
116. Czapińska-Ciepiela, E. K. (2017). [The risk of epileptic seizures during antibiotic therapy].. PubMed.
117. Daccache, G., Jeanne, M., & Fletcher, D. (2017). The Analgesia Nociception Index: Tailoring Opioid Administration. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000002145
118. Daisley, A., Tams, R., & Kischka, U. (2008). Changes in emotions and behaviour. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780199218226.003.0007
119. Daley, D. C., & Douaihy, A. (2019). Medications for Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0006
120. Daley, D. C., & Douaihy, A. (2019). Substance-Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0002
121. Davies, J. B., Saunders, W., & Helfgott, S. (2018). What is addiction?. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198797746.003.0001
122. DeJong, R. N. (1969). Memory Loss due to Hippocampal Lesions. Archives of Neurology. https://doi.org/10.1001/archneur.1969.00480100015001
123. Delgado, D. A. O., Rojas, M. C. O., & Olea, J. M. S. (2024). Episodio depresivo mayor de características catatónicas: Reporte de caso. Revista Científica de Salud y Desarrollo Humano. https://doi.org/10.61368/r.s.d.h.v5i1.75
124. Deng, S., Sheng, H.-Z., Zhou, Y., & Zhang, J. (2019). Whether we could forget pain or not after the scar healed? A discussion about changing the acute pain into chronic pain. Pain Clin J. https://doi.org/10.3760/cma.j.issn.1672-9633.2019.05.003
125. Deses, C. D. D. L. (2018). Alteraciones del sueño en personas adultas mayores. Revista de la Facultad de Medicina (México).
126. Devlin, R. J., & Henry, J. A. (2008). Clinical review: Major consequences of illicit drug consumption. Critical Care. https://doi.org/10.1186/cc6166
127. Dhar, N., Shree, R., Radhakrishnan, D. M., & Kumar, N. (2020). Hearing Loss in Migraine: An Uncommon Manifestation of a Common Disorder. Journal of Neurosciences in Rural Practice. https://doi.org/10.1055/s-0040-1713337
128. Dhingra, L., Ahmed, E., Shin, J. G., Scharaga, E., & Magun, M. (2015). Cognitive Effects and Sedation. Pain Medicine. https://doi.org/10.1111/pme.12912
129. Dietz, J., Klein, S. S., Biary, R., Blumberg, S., Roberts, S., Bercow, A., Goldwasser, B., & Hoffman, R. S. (2024). Pediatric opioid use-associated neurotoxicity with cerebellar edema (POUNCE) syndrome. Clinical Toxicology. https://doi.org/10.1080/15563650.2024.2435396
130. Dodge, N. C., Jacobson, J. L., Lundahl, L. H., & Jacobson, S. W. (2023). Prenatal alcohol exposure and attention‐deficit/hyperactivity disorder independently predict greater substance use in young adulthood. Alcohol Clinical and Experimental Research. https://doi.org/10.1111/acer.15076
131. Dolinak, D. (2017). Opioid Toxicity. Academic Forensic Pathology. https://doi.org/10.23907/2017.003
132. Domínguez, L. N., Martin, P. R., Olea, A. M., Martínez, N. B., Sanjosé, G. U., González, M. M., & Tolosa-Delgado, A. (2016). Atypical Psychotic Symptoms in Lafora´s Disease: A Case Report.
133. Dubovický, M. (2010). Neurobehavioral manifestations of developmental impairment of the brain. Interdisciplinary Toxicology. https://doi.org/10.2478/v10102-010-0012-4
134. Dubovsky, S. (2019). Maintenance Treatment for Opioid Dependence Does Not Increase Psychiatric Symptoms. Journal watch. https://doi.org/10.1056/nejm-jw.na48225
135. Duletic, N., Mijatovic-Papic, T., Cizmovic, B., & Kusturica, S. (2015). Differential Diagnostic Consideration of the Syndrome of Psychomotor Agitation in Geriatric Population. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)31130-5
136. Duma, S., & Fung, V. S. (2019). Drug-induced movement disorders. Australian Prescriber. https://doi.org/10.18773/austprescr.2019.014
137. Dydyk, A. M., Jain, N., & Gupta, M. (2021). Opioid Use Disorder.
138. Díaz, C. I. E., Maroto, G. A., Barrionuevo, M. C., Moya, J. E., Acosta, J. S., Procel, A. A., Pérez, J. R., & Jaya, A. C. A. (2020). Prevalencia, factores de riesgo y características clínicas de la parálisis cerebral infantil. AVFT – Archivos Venezolanos de Farmacología y Terapéutica.
139. Ebenezer, I. S. (2015). Drug Abuse and Addiction. https://doi.org/10.1002/9781118385777.ch11
140. Ebenezer, I. S. (2015). Sleep and Sleep Disorders. https://doi.org/10.1002/9781118385777.ch9
141. Echater, S., Hasnaoui, M., Saadi, I., Oneib, B., & Elghazouani, F. (2023). Temporomandibular joint dislocation due to neuroleptic-induced acute dystonia: case report. Revue Medicale de Bruxelles. https://doi.org/10.30637/2023.22-008
142. El-Hadi, S. M., Alkader, A. A. Z. A., Elwafa, R. A. H. A., Mohamed, E. D., & Azim, R. A. E. A. (2024). Effect of sevoflurane versus propofol on early cognitive functions in elderly patients after lumbar disc surgery. Egyptian Journal of Anaesthesia. https://doi.org/10.1080/11101849.2023.2300852
143. Elikowski, W., Małek‐Elikowska, M., Fertała, N., & Zawodna-Marszałek, M. (2021). Amiodarone-induced musical hallucinations.. PubMed.
144. Elliott, M., Terrett, G., Curran, H. V., Rendell, P. G., & Henry, J. D. (2023). Episodic foresight is impaired following acute alcohol intoxication. Journal of Psychopharmacology. https://doi.org/10.1177/02698811231154851
145. Ellis, J. D., Han, D. C., Mayo, J. L., Hobelmann, J. G., Finan, P. H., & Huhn, A. S. (2024). The association of pain impact and sleep disruption with opioid withdrawal during opioid‐use disorder treatment. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16022
146. Escande, M., & Boucard, J. (1999). [Atypical depression].. PubMed.
147. Eskander, F. S. L., Hakim, K. Y. K., Ibrahim, D., & ElMallah, W. (2021). Incidence Of Post-Operative Delirium In Geriatric Patients Undergoing Hip Replacement Surgery Using Pre-Operative Haloperidol. QJM. https://doi.org/10.1093/qjmed/hcab086.109
148. Fareed, A. M., Stout, S. C., Casarella, J., Vayalapalli, S., Cox, J., & Drexler, K. (2011). Illicit Opioid Intoxication: Diagnosis and Treatment. Substance Abuse Research and Treatment. https://doi.org/10.4137/sart.s7090
149. Farne, H., Norris-Cervetto, E., & Warbrick‐Smith, J. (2015). Blackout. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198716228.003.0009
150. Farooq, N. S. M. U., Alex, A., & Matthews, R. (2016). Opioid Medications: Psychiatric Diagnosis. Journal of Addiction Research & Therapy.
151. Fasmer, O. B., & Øedegaard, K. J. (2002). Are Migraines and Bipolar Disorder Related.
152. Fatma, S., Sunarti, S., Mardhiyah, F., Wirabhatari, A., & Winstonly, B. (2024). Tantangan Dalam Penilaian Klinis Gejala Depresi pada Usia Lanjut. Jurnal Klinik dan Riset Kesehatan. https://doi.org/10.11594/jk-risk.03.2.6
153. Fernández-Egea, E., & Jones, P. B. (2023). Schizophrenia. Cambridge University Press eBooks. https://doi.org/10.1017/9781911623137.065
154. Ferreira, K. V., & Melo, N. N. D. (2018). DEPRESSÃO EM IDOSOS: o papel do profissional farmacêutico. Psicologia e Saúde em Debate. https://doi.org/10.22289/2446-922x.v4n1a3
155. Ferreira, M. D. C., Varanda, S., Carneiro, G., Santos, B. H. D., & Machado, Á. (2016). Parkinson disease psychosis – A case report. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.258
156. Filho, A. C. O., Gomes, L. M. T., Corrêa, A. C., Leão, E. F. D., Cangussu, D. M., & Torres, S. D. A. S. (2019). BRUXISMO DO SONO. Revista Intercâmbio.
157. Finegan, W. C., McGurk, A., O’Donnell, W., Pederson, J., & Rogerson, E. (2018). Opioid-induced sedation. CRC Press eBooks. https://doi.org/10.4324/9781315378527-43
158. Frean, J., Jong, G. D., & Albrecht, R. (2008). Imaginary bugs, real distress: delusional parasitosis.. PubMed.
159. Freitas, D. F. D., Teixeira-Ribeiro, R., Bouça, J., Fernandes, N., Duarte, J., & Morgado, P. (2015). Metformin-induced Psychosis: a Case Report.. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)31423-1
160. Frymark, T., Leech, H. M., Mullen, R., Schooling, T., Venediktov, R., & Wang, B. (2010). Evidence-Based Systematic Review (EBSR): Drug-Induced Hearing Loss— Aminoglycosides.
161. Galasko, D. (2019). Pharmacological Approaches To Behavioral Symptoms In Alzheimer’s Disease. CRC Press eBooks. https://doi.org/10.1201/9780429260353-28
162. Gallo, P. (2019). [Opioid-induced constipation in oncologic patient: a clinical case treated with naloxegol].. PubMed. https://doi.org/10.1701/3132.31184
163. Gani, H. (2016). Risk Factors: Pathogenesis, Diagnosis and Management of Delirium. International Journal of Science and Research (IJSR). https://doi.org/10.21275/v5i4.nov162972
164. Garcia, A. B. (2019). Estudio de los efectos del tratamiento con antidepresivos sobre el consumo de alcohol.
165. Garcia, M. O., Garnica, M. M., Marin, S. G., Martínez, C., Martínez, R. G., & Valle, P. B. D. (2017). A child with Pica. A case presentation. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.472
166. García, M. D. S., & Calderón, R. M. (2010). Síntomas no motores en la enfermedad de Parkinson y estimulación cerebral profunda. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009745
167. García, M. D. S., & Calderón, R. M. (2012). Complicaciones de la estimulación cerebral profunda en la enfermedad de Parkinson. Revista de Neurología. https://doi.org/10.33588/rn.54s05.2012530
168. García, M. M., Lupiañez, I. J., Llaría, M. M. M., Guamanarca, R. I. S., Loraque, N. B., & Rubio, A. L. (2025). ESQUIZOFRENIA DESPUÉS DE LOS 65, UN DESAFÍO DIAGNÓSTICO.. Revista sanitaria de investigación.. https://doi.org/10.34896/rsi.2025.81.58.001
169. García, R. G., Alvarez, M. R., & Arturo, F. (2010). Cefalea por uso excesivo de medicamentos: implicaciones clínicas y terapéuticas Medication over use headache: clinical and therapeutic implications.
170. Garg, T., & Rawat, V. S. (2023). Trihexyphenidyl Use Disorder and Withdrawal Syndrome. Journal of Psychiatry Spectrum. https://doi.org/10.4103/jopsys.jopsys_12_23
171. Garro, A., Bond, G. R., & Gilbert, D. L. (2007). Dyskinesias associated with atomoxetine in combination with other psychoactive drugs. Clinical Toxicology. https://doi.org/10.1080/15563650600981178
172. George, O., & Koob, G. F. (2017). Individual differences in the neuropsychopathology of addiction. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2017.19.3/gkoob
173. Gera, A., Garg, S., & Mittal, S. (2023). Generalized myoclonus restricted to the “Smack” withdrawal state: A rare case report. Archives of Biological Psychiatry. https://doi.org/10.25259/abp_32_2023
174. Ghaemi, S. N. (2018). Children. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199995486.003.0028
175. Ghaisani, N. (2018). Potensi Ketamin Dosis Rendah untuk Penderita Depresi Berat. JIMKI Jurnal Ilmiah Mahasiswa Kedokteran Indonesia.
176. Ghosh, R., Lahiri, D., Dubey, S., Ray, B. K., & Benito‐León, J. (2020). Hallucinatory Palinopsia in COVID-19-Induced Posterior Reversible Encephalopathy Syndrome. Journal of Neuro-Ophthalmology. https://doi.org/10.1097/wno.0000000000001135
177. Ghosh, S. (2015). Better understanding of etiopathology needed to develop novel treatments. Medicus.
178. Giliberti, A., Frisina, A. M., Giustiniano, S., Carbonaro, Y., Roccella, M., & Nardello, R. (2025). Autism Spectrum Disorder and Epilepsy: Pathogenetic Mechanisms and Therapeutic Implications. Journal of Clinical Medicine. https://doi.org/10.3390/jcm14072431
179. Giorelli, A. S., Santos, P. P. D., Carnaval, T., & Gomes, M. D. M. (2012). Sonolência excessiva diurna: aspectos clínicos, diagnósticos e terapêuticos Excessive daytime sleepiness: clinical, diagnostic and therapeutic aspects.
180. González, R. M., Quesada, H. S., & Sancho, L. V. (2010). Episodio mixto secundario al uso de fluoxetina en una paciente con un transtorno afectivo bipolar no diagnosticado. Revista Médica de Costa Rica y Centroamérica.
181. Gordon, M. F., & Leder, A. (2012). Serotonin Syndrome. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-835-5_18
182. Graddy, R., & Rastegar, D. A. (2020). Stimulants. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0008
183. Grannell, L. (2020). Drug interaction resources: mind the gaps. Australian Prescriber. https://doi.org/10.18773/austprescr.2020.005
184. Griswold, K., Regno, P. A. D., & Berger, R. C. (2015). Recognition and Differential Diagnosis of Psychosis in Primary Care.. PubMed.
185. Grover, S., Sarkar, S., & Avasthi, A. (2022). Clinical Practice Guidelines for Management of Medical Emergencies Associated with Psychotropic Medications. Indian Journal of Psychiatry. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_1013_21
186. Guamanarca, R. I. S., Loraque, N. B., Rubio, A. L., García, M. M., Lupiañez, I. J., & Llaría, M. M. M. (2025). SÍNDROME DE EKBOM EN PACIENTE GERIÁTRICO. A PROPÓSITO DE UN CASO.. Revista sanitaria de investigación.. https://doi.org/10.34896/rsi.2025.31.47.002
187. Gudin, J., Laitman, A. P., & Nalamachu, S. (2015). Opioid Related Endocrinopathy: Table 1. Pain Medicine. https://doi.org/10.1111/pme.12926
188. Guly, H. R. (2004). Substance abuse and the trauma patient. Trauma. https://doi.org/10.1191/1460408604ta315oa
189. Gupta, D., & O’Hara, C. (2019). Aripiprazole Toxicity With a Biphasic Course of Somnolence. Pediatric Emergency Care. https://doi.org/10.1097/pec.0000000000001889
190. Gutierrez, M. R. R., & Corona, L. R. (2008). Síndrome de encefalopatía hiponatremica osmótica en el curso de un coma alcohólico. Presentación de un caso. MULTIMED.
191. Gutiérrez-Achury, A. M., Vanegas-Vidal, M., Salazar-Díaz, L. I., & Arías, G. M. A. (2009). Factores farmacológicos y no farmacológicos que afectan la adherencia al tratamiento de los pacientes esquizofrénicos dados de alta en la Unidad de Salud Mental del Hospital Universitario de Neiva entre enero y junio del 2008. RFS Revista Facultad de Salud. https://doi.org/10.25054/rfs.v1i2.43
192. Gutmann, L., Farrell, B., Crosby, T. W., & Johnsen, D. C. (1980). Nitrous Oxide-Induced Myelopathy-Neuropathy. Survey of Anesthesiology. https://doi.org/10.1097/00132586-198002000-00020
193. Hachey, L. M., Gregg, J. A., Pavlik-Maus, T. L., & Jones, J. S. (2017). Health implications and management of women with opioid use disorder. Journal of Nursing Education and Practice. https://doi.org/10.5430/jnep.v7n8p57
194. Hadi, I., Wijayati, F., Usman, R. D., & Rosyanti, L. (2017). Major Depressive Disorder: A Mini Review. Health Information Jurnal Penelitian. https://doi.org/10.36990/hijp.v9i1.102
195. Hainline, B., Gurin, L., & Torres, D. M. (2019). Cognitive Dysfunction Following Concussion. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0034
196. Halbauer, J. D., Ashford, J. W., Zeitzer, J. M., Adamson, M. M., Lew, H. L., & Yesavage, J. A. (2009). Neuropsychiatric diagnosis and management of chronic sequelae of war-related mild to moderate traumatic brain injury. The Journal of Rehabilitation Research and Development. https://doi.org/10.1682/jrrd.2008.08.0119
197. Hamed, S. A. (2017). The auditory and vestibular toxicities induced by antiepileptic drugs. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2017.1372420
198. Hamed, S. A. (2018). Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: presentations, causes, and treatment strategies. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2019.1555468
199. Hamza, S., Heba, G., & Am, N. (2019). Relationship between Sleep Disturbance and Polypharmacy among Hospitalized Elderly. Egyptian Journal of Geriatrics and Gerontology. https://doi.org/10.21608/ejgg.2019.139022
200. Hansen, J. (2016). Basics of Opioid Pharmacology.. PubMed.
201. Hawkes, M. A., & Hocker, S. E. (2021). Status Epilepticus. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0057
202. Henkin, R. I., & Abdelmeguid, M. (2020). Smell Loss and Onset of Phantosmia are Critical Aspects of Head Injury Cognition. The FASEB Journal. https://doi.org/10.1096/fasebj.2020.34.s1.02320
203. Heuser, K., Olsen, K. B., Ulvin, L. B., Gjerstad, L., & Taubøll, E. (2022). Modern Treatment of Status Epilepticus in Adults. Exon Publications eBooks. https://doi.org/10.36255/exon-publications-epilepsy-status-epilepticus
204. Hill, K. (2021). A fear of dogs. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0011
205. Howes, O., McDonald, C., Cannon, M., Arseneault, L., Boydell, J., & Murray, R. (2004). Pathways to schizophrenia: the impact of environmental factors. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145704004122
206. Hristovska, A., Uldall-Hansen, B., Mehlsen, J., Kehlet, H., & Foss, N. B. (2022). Orthostatic intolerance after intravenous administration of morphine: incidence, haemodynamics and heart rate variability analysis. Anaesthesia. https://doi.org/10.1111/anae.15945
207. Hsieh, M. T., Peng, W., Wu, C., Ng, K., Cheng, C. Y., & Xu, H. (2010). None. Planta Medica. https://doi.org/10.1055/s-002-20741
208. Huhn, A. S., & Ellis, J. D. (2022). Commentary on Zolopa <i>et al</i> .: Trauma as an impediment to successful aging and a precipitant of opioid and stimulant use among older adults. Addiction. https://doi.org/10.1111/add.15877
209. Hyytiä, P. (2015). [The effect of abused drugs on the developing brain during childhood and adolescence].. PubMed.
210. Inguscio, L., Caponnetto, P., Valeri, S., Maglia, M., Polosa, R., Lai, C., & Mazzoni, G. (2021). Smartphone addiction through age and gender during Italian lockdown for COVID-19. Proceedings of The 3rd International Electronic Conference on Environmental Research and Public Health —Public Health Issues in the Context of the COVID-19 Pandemic. https://doi.org/10.3390/ecerph-3-09027
211. Iversen, L. L., Iversen, S. D., Bloom, F. E., & Roth, R. H. (2009). Psychedelics. Oxford University Press eBooks. https://doi.org/10.1093/med/9780195380538.003.0606
212. Jahan, A. R., & Burgess, D. M. (2021). Substance Use Disorder. StatPearls.
213. Jain, S., Goel, S., & Kapila, S. (2015). Clinical Evaluation Of Psychiatric Emergencies.
214. Jang, J.-H., Jung, K., Kim, J., Jung, I. C., Yoo, H.-R., & Moon, C. (2018). Potential Application of Yokukansan as a Remedy for Parkinson’s Disease. Evidence-based Complementary and Alternative Medicine. https://doi.org/10.1155/2018/1875928
215. Janiani, A., Ali, T., Garg, G., Chaudhury, S., Javedekar, A., & Singh, A. (2024). Alcohol-induced psychotic disorder with hallucinations (alcoholic hallucinosis): A case series. Industrial Psychiatry Journal. https://doi.org/10.4103/ipj.ipj_310_23
216. Jargin, S. V. (2019). Some aspects of tobacco smoking in the context of alcohol drinking, hangover and mental health problems. International Journal of Psychiatry Research. https://doi.org/10.33545/26648962.2019.v1.i2a.10
217. Jaspal, H., Neupane, D., & Madhusoodanan, S. (2019). Coprophagia in an older adult with Schizophrenia- A case report and brief review. Medical Case reports and Reviews. https://doi.org/10.15761/mcrr.1000135
218. Jiménez, C., & Belén, M. (2019). Terapia de aceptación y compromiso grupal aplicada a pacientes adictos a los opioides con el manejo de los síntomas de abstinencia junto con la terapia farmacológica para evitar recaídas a futuro.
219. Jones, D. T. (2019). Minimally Conscious State and Persistent Vegetative State. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190862923.003.0141
220. Jones, J. D., Luba, R., Mumtaz, M., & Castillo, F. (2023). Opioid Overdose: Mechanisms and Naloxone. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780197618431.013.30
221. Jourdet, N. (2018). Les céphalées par abus médicamenteux : Prévention par le bon usage des médicaments indiqués dans les céphalées primaires. Usage problématique des opioïdes.
222. Jukić, M. K., Mimica, N., & Lucijanić, D. (2024). DEPRESSION IN ELDERLY PERSONS. Proceedings. https://doi.org/10.62598/9thicva.019
223. Juruena, M. F. (2009). Exposição ao chumbo: consequências neuropsiquiátricas e comportamentais. Medicina (Ribeirão Preto). https://doi.org/10.11606/issn.2176-7262.v42i3p296-300
224. Kaczyńska, K., & Wojciechowski, P. (2021). Non-Opioid Peptides Targeting Opioid Effects. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms222413619
225. Kaggwa, M. M., Nkola, R., Najjuka, S. M., Bongomin, F., Ashaba, S., & Mamun, M. A. (2021). Extrapyramidal Side Effects in a Patient with Alcohol Withdrawal Symptoms: A Reflection of Quality of the Mental Health Care System. Risk Management and Healthcare Policy. https://doi.org/10.2147/rmhp.s314451
226. Kahn, T., Cosme, R., Begolli, M., & Addepalli, R. (2012). A Case of Zolpidem-induced Hepatic Encephalopathy in a Patient with Major Depression. Jefferson Journal of Psychiatry. https://doi.org/10.29046/jjp.024.1.002
227. Kanellopoulos, D., & Vallejo, P. S.-B. (2019). Substance Related Cognitive Dysfunction in Aging. Clinical handbooks in neuropsychology. https://doi.org/10.1007/978-3-319-93497-6_19
228. Kara, W. A., Bakari, K. H., Mayala, H., Shao, B., & Mao, J. (2017). Neurocognitive Effects of Electroconvulsive Therapy in Psychiatric Disorders, Mechanism of Action And its Prevention: Review Article. IOSR Journal of Dental and Medical Sciences. https://doi.org/10.9790/0853-1604078792
229. Karila, L., Lowenstein, W., Coscas, S., Benyamina, A., & Reynaud, M. (2009). [Complications of cocaine addiction].. PubMed.
230. Karssemeijer, E. G., Heijden, C. D. V. D., Wolters, T. L. C., Boekhorst, B. T., Avest, M. T., & Kramers, C. (2021). [Don't stop medication too abruptly: advice about the discontinuation of medication]..
231. Karssemeijer, E. G., Heijden, C. D. V. D., Wolters, T. L. C., Boekhorst, B. T., Avest, M. T., & Kramers, C. (2021). [Don't stop medication too abruptly: advice about the discontinuation of medication].. PubMed.
232. Kasahara, S., Kato, Y., Takahashi, M., Matsudaira, K., Sato, N., Niwa, S., Momose, T., & Uchida, K. (2023). Case report: Remission of chronic low back pain and oral dysesthesia comorbid with attention deficit/hyperactivity disorder by treatment with atomoxetine and pramipexole. Frontiers in Pain Research. https://doi.org/10.3389/fpain.2023.1159134
233. Kattan, J. D. (2015). Anaphylaxis. https://doi.org/10.1002/9781118609125.ch29
234. Keam, S. J., & Walker, M. C. (2007). Therapies for narcolepsy with or without cataplexy: evidence-based review. Current Opinion in Neurology. https://doi.org/10.1097/wco.0b013e3282f22ad9
235. Kim, G. S., Nunez, T., & Vargas, E. (2021). Omeprazole-induced Visual Hallucinations: A Case Report. Journal of Psychiatric Practice. https://doi.org/10.1097/pra.0000000000000575
236. Kim, H., Park, C. I., Kim, H. W., Kang, J. I., & Kim, S. J. (2019). INFLUENCE OF DOPAMINE-RELATED GENES ON PROBLEMATIC DRINKINGS, IMPULSIVITY AND AGGRESSION IN KOREAN MALE PATIENTS WITH ALCOHOL USE DISORDER. https://doi.org/10.26226/morressier.5d1a037057558b317a14008c
237. Kleber, H. D. (2007). Pharmacologic treatments for opioid dependence: detoxification and maintenance options.. PubMed.
238. Knapp, P., & Lightbody, C. E. (2019). Emotional and Cognitive Changes Following a Stroke. https://doi.org/10.1002/9781119581161.ch11
239. Ko, J. Y., Wolicki, S. B., Barfield, W. D., Patrick, S. W., Broussard, C. S., Yonkers, K. A., Naimon, R., & Iskander, J. (2017). CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome. MMWR Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm6609a2
240. Koch, T., Schulz, S., & Höllt, V. (2003). Different Intracellular Signaling Systems Involved in Opioid Tolerance/Dependence. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_4
241. Kojima, T., & Akishita, M. (2016). [Drug-induced dementia].. PubMed.
242. Kolla, B., & Hocker, S. E. (2021). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0045
243. Kosten, T., & George, T. P. (2002). The Neurobiology of Opioid Dependence: Implications for Treatment. Science & Practice Perspectives. https://doi.org/10.1151/spp021113
244. Kovalenko, A. L., Sinenchenko, A. G., & Lodyagin, A. N. (2022). [CLINICAL CASE OF ACUTE SEVERE COMBINED POISONING WITH NARCOTIC SUBSTANCES OF DEPENDENT AND PSYCHOSTIMULATING EFFECTS].. PubMed.
245. Koçer, E., Alçelik, A., & Canan, F. (2011). Olanzapine Intoxication-Related Transient Diabetes Insipidus. Renal Failure. https://doi.org/10.3109/0886022x.2011.599094
246. Kramer, L. D., Locke, G. E., Ogunyemi, A. O., & Nelson, L. (1990). Cocaine-Related Seizures in Adults. The American Journal of Drug and Alcohol Abuse. https://doi.org/10.3109/00952999009001592
247. Ksiądzyna, D., Merwid‐Ląd, A., Matuszewska, A., Grotthus, B., & Szeląg, A. (2019). Objawy odstawienia wybranych leków. Część I. Medycyna Rodzinna. https://doi.org/10.25121/mr.2019.22.1.27
248. Kumar, N., Mendonça, D. A., & Jog, M. (2017). Teaching Video Neuro <i>Images:</i> Lithium-induced reversible Pisa syndrome. Neurology. https://doi.org/10.1212/wnl.0000000000003892
249. Kumar, S., & Flemming, K. D. (2021). Syndromes of Cognitive Dysfunction. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0076
250. Kupka, R. W. (2021). Mental disorders in a dental practice. Psychomood disorders. Nederlands Tijdschrift voor Tandheelkunde. https://doi.org/10.5177/ntvt.2021.02.20101
251. Lader, M. (1999). 1. The Influence of Drugs upon Testimony. Medicine Science and the Law. https://doi.org/10.1177/002580249903900203
252. Lahiri, D., Lima, B. S., Roncero, C., Stokes, K. A., Panda, S. S., & Chertkow, H. (2024). Psychotropic Polypharmacy Leading to Reversible Dementia: A Case Report. Cognitive and Behavioral Neurology. https://doi.org/10.1097/wnn.0000000000000380
253. Laks, J., & Alford, D. P. (2024). Treatment of opioid use disorder in patients with liver disease. Clinical Liver Disease. https://doi.org/10.1097/cld.0000000000000207
254. Lambert, D. G. (2023). Opioids and opioid receptors; understanding pharmacological mechanisms as a key to therapeutic advances and mitigation of the misuse crisis. BJA Open. https://doi.org/10.1016/j.bjao.2023.100141
255. Lamboglia, A. L. C., Rossi, A., Yanes, F. B., & Larraz, G. A. G. (2024). Secuelas neurológicas tardías en la intoxicación por monóxido de carbono. Reporte de un caso pediátrico.. ARS MEDICA Revista de Ciencias Médicas. https://doi.org/10.11565/arsmed.v49i2.2023
256. Lara-Plaza, O., Solís‐Navarro, L., Rivera‐Lillo, G., & Torres‐Castro, R. (2022). Cognitive and motor performance effects of non-invasive brain stimulation in patients with traumatic brain injury: A meta-analysis of randomised controlled trials. https://doi.org/10.37766/inplasy2022.4.0067
257. Latt, N., Conigrave, K. M., Saunders, J. B., Marshall, E. J., & Nutt, D. (2009). Chapter 10 Other drugs. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199539338.003.0010
258. Lavigne, G., Babiloni, A. H., Beetz, G., Fabbro, C. D., Sutherland, K., Huynh, N., & Cistulli, P. A. (2019). Critical Issues in Dental and Medical Management of Obstructive Sleep Apnea. Journal of Dental Research. https://doi.org/10.1177/0022034519885644
259. Law, F., Praveen, K. T., O’Shea, J., & Melichar, J. (2011). Opioid dependence.. PubMed.
260. Lawrie, S. M., MacHale, S., Power, M., & Goodwin, G. M. (1997). EDITORIAL. Psychological Medicine. https://doi.org/10.1017/s0033291797005370
261. Leal, J. L. V., Hoyos-Zuluaga, C., & Álvarez, J. Z. (2022). ¿Psicosis luego de sobredosis por opioides? Lesión isquémica bilateral del globo pálido como causa orgánica insospechada.. Revista de Neuro-Psiquiatría. https://doi.org/10.20453/rnp.v85i4.4371
262. Lee, X.-C., Lu, T., Zheng, W., & Xue, Y. (2025). STRESS COMBINED WITH EXTINCTION PREVENTS COCAINE RELAPSE BY DISRUPTING MEMORY. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae059.175
263. Lee, Y. L., Wong, J., & Ng, S. Y. (2022). Delirium in patients following general anaesthesia. Annals of the Academy of Medicine Singapore. https://doi.org/10.47102/annals-acadmedsg.202228
264. Leikin, J. B. (2018). Toxicologic Malingering. CRC Press eBooks. https://doi.org/10.1201/9781351059633-8
265. Lepping, P., Huber, M., & Freudenmann, R. W. (2015). How to approach delusional infestation. BMJ. https://doi.org/10.1136/bmj.h1328
266. Levy, T., Silver, H., Soufer, R., Rouhandeh, A., Kolevzon, A., Buxbaum, J. D., & Siper, P. M. (2025). Adolescents and adults with FOXP1 syndrome show high rates of anxiety and externalizing behaviors but not psychiatric decompensation or skill loss. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2025.1526383
267. Lewis, D., & Woods, S. E. (1994). Fetal alcohol syndrome.. PubMed.
268. Lečić-Toševski, D. M., Pejović-Milovančević, M., Popović-Deušić, S., & Šušić (2007). [Psychiatric aspects of sleep].. PubMed.
269. Ligier, F., & Kabuth, B. (2016). Between Neurology and Psychiatry, a Difficult Preliminary Diagnosis of Kleine-levin Syndrome: Case-report of a Young Girl. Journal of Child and Adolescent Behaviour. https://doi.org/10.4172/2375-4494.1000274
270. Limandri, B. J. (2018). Benzodiazepine Use: The Underbelly of the Opioid Epidemic. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20180521-03
271. Lin, S. (2019). Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion?. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyz068
272. Lipman, A. G. (1990). Clinically relevant differences among the opioid analgesics. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/47.8_suppl_1.s7
273. Liu, G., Slater, N., & Perkins, A. (2017). Epilepsy: Treatment Options.. PubMed.
274. Liu, J., & JunHong, Y. (2010). The signal transudations mechanism of opioid dependence and withdrawal. Xiandai shengwu yixue jinzhan.
275. Llcms, L. C., Martins, P. R. C., Loures, É. N., Vitalino, A. R., Lotufo, C. C., & Onady, S. Y. (2017). ATAQUE ISQUÊMICO TRANSITÓRIO E ESTADO DE MAL EPILÉPTICO COMO MANIFESTAÇÕES DE INTOXICAÇÃO AGUDA E ABSTINÊNCIA POR CRACK E COCAÍNA.
276. Logan, B. K., & Couper, F. J. (2003). 3,4-Methylenedioxymethamphetamine - Effects on Human Performance and Behavior.. PubMed.
277. Loitman, J. E., & Deshields, T. L. (2010). Psychiatric Palliative Care Issues. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-590-3_4
278. Louis, E. K. S., Boeve, A., & Boeve, B. F. (2017). <scp>REM</scp><scp>S</scp>leep <scp>B</scp>ehavior <scp>D</scp>isorder in <scp>P</scp>arkinson's <scp>D</scp>isease and <scp>O</scp>ther <scp>S</scp>ynucleinopathies. Movement Disorders. https://doi.org/10.1002/mds.27018
279. Lucassen, P., Ligthart, S. A., Kramers, C., & Speckens, A. (2021). [Why do patients find it difficult to discontinue their medication?]. PubMed.
280. Lukas, A., Harsono, H., & Astuti, A. (2016). GANGGUAN KOGNITIF PADA EPILEPSI. Berkala Ilmiah Kedokteran Duta Wacana. https://doi.org/10.21460/bikdw.v1i2.10
281. Lutfy, K. (2020). Opioid Crisis—An Emphasis on Fentanyl Analogs. Brain Sciences. https://doi.org/10.3390/brainsci10080485
282. Lynch, T. R., Cheavens, J. S., Cukrowicz, K. C., Thorp, S. R., Bronner, L., & Beyer, J. L. (2008). Tratamiento de personas mayores con trastorno de la personalidad y depresión comórbida: un acercamiento a la terapia conductual dialéctica. RET: revista de toxicomanías.
283. López, A. M., Martínez, L. R. D., & Moreno, J. (2012). Uso de marcadores bioquímicos para valoración de riesgo de crisis convulsivas en el síndrome de supresión etílica. Salud Mental.
284. López, C. A., Fernández, D. S., López, M. M., Gázquez, M. C. G., & Pérez, A. V. (2019). Cuidados de enfermería en recién nacidos con síndrome de abstinencia.
285. López, S. S. D. M., & Márquez, J. (2016). Evolución y situación actual del consumo deantidepresivos en España.
286. M.E., B., VergelHernández, J., C.A., H., C.S., M., Ospina-Otálvaro, S., J.D., S., P.M., A., J.J., A., Basic, A. C. N. S. R. T. O., & Psychiatry, S. O. M. R. T. O. (2021). Supplementary Material for: Neuropsychiatric Aspects in a Patient Diagnosed with Frontotemporal Dementia: Clinical Case of Low Incidence and Prevalence Disease in Colombia. Figshare. https://doi.org/10.6084/m9.figshare.14932008
287. Machado, C. F. A., & Siqueira, E. C. D. (2022). Uma abordagem geral do Transtorno de Estresse Pós-Traumático: revisão de literatura. Revista Eletrônica Acervo Médico. https://doi.org/10.25248/reamed.e10939.2022
288. Macho, L. P., & Andrés, S. B. (2010). Trastornos digestivos en la enfermedad de Parkinson: atonía gástrica, malabsorción y estreñimiento. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009740
289. Mahadevan, J., D’cruz, M., Chand, P., & Murthy, P. (2019). An interesting presentation of psychotic catatonia in an elderly patient with alcohol dependence. Journal of Geriatric Mental Health. https://doi.org/10.4103/jgmh.jgmh_33_19
290. Mahato, T. K., Ojha, S. K., Singh, V., & Parihar, S. P. S. (2021). Addiction withdrawal syndrome: Needs medications, education, counselling &amp; support. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2021.12.2.0573
291. Mahon, S. M., & Carr, E. (2021). Cognitive Dysfunction: Common Side Effect. Clinical journal of oncology nursing. https://doi.org/10.1188/21.cjon.s2.23
292. Mailman, R. B., & Murthy, V. (2010). Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?. Current Pharmaceutical Design. https://doi.org/10.2174/138161210790361461
293. Majeske, M., Nistor, V., & Kellner, C. H. (2016). Late‐Life Psychosis. https://doi.org/10.1002/9781118654231.ch35
294. Mameli, M. (2009). Controlling the persistence of drug-evoked plasticity in the mesolimbic dopamine system. https://doi.org/10.13097/archive-ouverte/unige:2138
295. Mangas, M. C., & Feliu, M. R. (2012). P-890 - Acute psychosis induced by anabolic steroids. European Psychiatry. https://doi.org/10.1016/s0924-9338(12)75057-5
296. Mangastuti, R. S., Rahardjo, S., & Wargahadibrata, A. H. (2016). Penatalaksanaan Anestesi pada Operasi Epilepsi. Jurnal Neuroanestesi Indonesia. https://doi.org/10.24244/jni.vol5i2.64
297. Marcello, S., & Silverstein, S. M. (2010). Schizophrenia. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0820
298. Maremmani, I., Pacini, M., Lamanna, F., Pani, P., Perugi, G., Deltito, J., Salloum, I. M., & Akiskal, H. S. (2010). Mood Stabilizers in the Treatment of Substance Use Disorders. CNS Spectrums. https://doi.org/10.1017/s1092852900027346
299. Marouf, R., Chtioui, H., Girardin, F., Buclin, T., & Diezi, L. (2024). Pharmacovigilance. Sevrage et effet rebond: pas seulement avec les psychotropes. Revue Médicale Suisse. https://doi.org/10.53738/revmed.2024.20.856-7.96
300. Martins, B. A., Madureira, R. S., Freitas, R. C., & Guidoreni, C. G. (2017). Enxaqueca. Congresso Médico Acadêmico UniFOA.. https://doi.org/10.47385/cmedunifoa.451.4.2017
301. Martínez, A. R., Argüelles, P. P., Cucurella, M. M., Llort, A. J., Camacho, J. A., & Plana, J. C. (2008). Manifestaciones neurológicas en el síndrome hemolítico urémico. Revista de Neurología. https://doi.org/10.33588/rn.4704.2008249
302. Martínez, G., Rodríguez, L. S., & Barea, M. V. (2021). Narcolepsy and anxiety. Is this association possible?. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.1629
303. Marvanová, M. (2016). Drug-induced cognitive impairment: Effect of cardiovascular agents. Mental Health Clinician. https://doi.org/10.9740/mhc.2016.07.201
304. Marzal, G. P., Rigual, F. C., Soto, B. B., & Olivares, J. Q. (2015). Psicoestimulantes en la infancia: ¿Medicalización o mejoramiento?.
305. Mast, R., Harper, B., Pollock, K., & Gentile, J. P. (2019). Pharmacologic Treatment of Attention Deficit Disorder in Children and Adolescents: Executive Function Agents, Stimulants, and Sympathomimetic Amines. Journal of Clinical Medicine and Therapeutics.
306. Mattson, R. H. (2004). Cognitive, affective, and behavioral side events in adults secondary to antiepileptic drug use.. PubMed.
307. Mauri, M. C. (2016). Drug Induced Psychosis or Schizophrenia?. Dual Diagnosis Open Access. https://doi.org/10.21767/2472-5048.100011
308. McArdle, P., & Angom, B. (2012). Adolescent substance misuse: an update on behaviours and treatments. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.bp.106.003327
309. McIntyre, R. S., & Calabrese, J. R. (2019). Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2019.1636017
310. McQuillan, R. (2020). Symptoms other than pain. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0065
311. Meador, K. J. (2002). Cognitive outcomes and predictive factors in epilepsy. Neurology. https://doi.org/10.1212/wnl.58.8_suppl_5.s21
312. Mejía-Rodríguez, D., González, L. E. M., & Mejía, M. C. B. (2020). Intoxicaciones por bupropión: presentación de caso. Revista Médicas UIS. https://doi.org/10.18273/revmed.v33n2-2020014
313. Mendes, E. M., Mendes, A., Ribeiro, C. A. Á. S., & Guerra, D. (2018). Adult-onset epileptic aphasia. BMJ Case Reports. https://doi.org/10.1136/bcr-2018-225563
314. Menecier, P., & Rotheval, L. (2017). L’intoxication éthylique aiguë ou l’ivresse alcoolique. Médecine. https://doi.org/10.1684/med.2017.210
315. Mercadante, S. (1999). Opioid rotation for cancer pain. Cancer. https://doi.org/10.1002/(sici)1097-0142(19991101)86:9<1856::aid-cncr30>3.0.co;2-g
316. Mercadante, S. (2019). Opioid Analgesics Adverse Effects: The Other Side of the Coin. Current Pharmaceutical Design. https://doi.org/10.2174/1381612825666190717152226
317. Mercês, T. M. D. (2019). Controle hidroeletrolítico e respostas cardiovasculares à injeção central de angII, carbacol e hiperosmolaridade plasmática em ratos com epilepsia induzida por pilocarpina.
318. Mesa, M. O. N., & Bellido, R. L. (2009). Papel del Sistema Opioide Sobre el Procesamiento de la Memoria Evidencia clínica y experimental. Revista Colombiana de Medicina Física y Rehabilitación.
319. Michael, D. M., Branford, D., & Barrett, M. J. (2015). Bipolar Affective Disorder. https://doi.org/10.1002/9781118897164.ch16
320. Micoulaud‐Franchi, J., Bioulac, S., & Philip, P. (2017). Management of insomnia: drug approach. PubMed.
321. Midha, N. K., Misra, A. K., Chhabra, V., & Bohra, G. K. (2017). Olanzapine Overdose in a Pin Point Pupil with Altered Sensorium. https://doi.org/10.22038/apjmt.2017.9404
322. Mihanović, M., Bodor, D., Kezić, S., Restek-Petrović, B., & Silić, A. (2009). Differential diagnosis of psychotropic side effects and symptoms and signs of psychiatric disorders.. PubMed.
323. Miller, S., Schwemmle, C., Jungheim, M., Kühn, D., & Ptok, M. (2015). [Medication-induced dysphagia : A review]..
324. Mimica, N., Presečki, P., Jukić, M. K., & Vitezić, D. (2017). Pharmacotherapy in Alzheimer's disease.
325. Mina, S., Hajar, B., Hassnaa, S., Saadia, K., Sabrine, M., Imane, A., & Fatiha, M. (2023). Case Report of a Patient with Bipolar Disorder and Deafness. Scholars Journal of Medical Case Reports. https://doi.org/10.36347/sjmcr.2023.v11i04.084
326. Mir, J. A., Mushtaq, B., & Mushtaq, O. A. (2022). Clinical case report on bipolar affective disorder, mania. IP Journal of Paediatrics and Nursing Science. https://doi.org/10.18231/j.ijpns.2022.007
327. Mitra, S. (2018). Opioid-induced hyperalgesia: Pathophysiology and clinical implications. Journal of Opioid Management. https://doi.org/10.5055/jom.2008.0017
328. Mocanu, C., Cernea, D., Enache, M., & Deca, A. G. (2009). [General anesthesia in ophthalmology].. PubMed.
329. Modebelu, U., Nargarathan, P. K. M., Marleime, K., & Ramesh, K. (2019). Pharmacologic Therapy for Neonatal Abstinence Syndrome. Journal of Drug Delivery and Therapeutics. https://doi.org/10.22270/jddt.v9i3.2900
330. Mohapatra, S., & Panda, U. (2016). Neuropsychiatric manifestations following acute organophosphate poisoning. Medical Journal of Dr D Y Patil University. https://doi.org/10.4103/0975-2870.192163
331. Montag, D. (2021). Retrograde Amnesia – A Question of Disturbed Calcium Levels?. Frontiers in Cellular Neuroscience. https://doi.org/10.3389/fncel.2021.746198
332. Montalto, S. A. (2021). Intrapartum Asphyxia and Its Sequelae. Cambridge University Press eBooks. https://doi.org/10.1017/9781108863049.061
333. Monteiro, M. I., Ferreira, A., Grebe, H., Gomes, L., & Costa, M. M. D. (2016). Psiquiátrico, aditivo ou orgânico:  um desafio nos adolescentes. DOAJ (DOAJ: Directory of Open Access Journals).
334. Moorthi, K., Pertin, S., & Radhika, P. (2023). Homoeopathy for obsessive-compulsive disorder: A case report. Indian Journal of Research in Homoeopathy. https://doi.org/10.53945/2320-7094.1117
335. Moreira, G. F., Coscarelli, L. P., Jardim, M. C. D., Araújo, I. M. M., Grossi, B. D., Guidi, R. A., Menezes, Y. C. D. C., Silva, I. M., Calmon, M. Z., Neto, C. A. B., Santiago, D. S. D. P., Santos, V. H. R., Souza, L. L., & Silva, C. E. P. (2022). Atualizações sobre a doença de Alzheimer e seus estágios clínicos. Brazilian Journal of Health Review. https://doi.org/10.34119/bjhrv5n6-016
336. Mudgal, V., Mishra, S., Mathur, R., & Dua, S. (2025). The Sound of Obsession: An Unusual Case Report of Misophonia and Obsessive–Compulsive Disorder. Annals of Indian Psychiatry. https://doi.org/10.4103/aip.aip_158_23
337. Munir, S., & Takov, V. (2021). Generalized Anxiety Disorder. StatPearls.
338. Munster, B. C. V., Rooij, S. E. D., & Inouye, S. K. (2016). Delirium, drugs, toxins. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199655946.003.0022
339. Murar, E. A., Taheri, S., & Memari, S. A. (2024). History Taking and Management of a Patient Presenting with Tremor. https://doi.org/10.1007/978-981-99-5530-5_13
340. Murty, V. L., Baid, G. C., Sharma, S., Singh, S. K., Lath, V., & Jena, P. (2023). Obstructive Sleep Apnea: A Prosthodontist’s Viewpoint. Scholars Journal of Dental Sciences. https://doi.org/10.36347/sjds.2023.v10i05.005
341. Mushthi, D., Chakraborty, R., Chaudhury, S., & Singh, A. (2025). Olanzapine-induced akathisia treated with clozapine. Industrial Psychiatry Journal. https://doi.org/10.4103/ipj.ipj_268_24
342. Müller, D., Angerer, V., Kithinji, J., Auwärter, V., Neurath, H., Liebetrau, G., Just, S., & Hermanns‐Clausen, M. (2016). Desoxypipradrol – eine neue (alte) Designerdroge. DMW - Deutsche Medizinische Wochenschrift. https://doi.org/10.1055/s-0042-107537
343. Müller‐Lissner, S. (2019). Obstipation – Pathophysiologie, Diagnostik, Behandlung. DMW - Deutsche Medizinische Wochenschrift. https://doi.org/10.1055/a-0670-5209
344. N.G., E., & Zashchirinskaia, O. V. (2024). ATTITUDE TO THE DISEASE AND ADHERENCE TO TREATMENT OF PATIENTS WITH CONSEQUENCES OF STROKE. “Educational bulletin “Consciousness”. https://doi.org/10.26787/nydha-2686-6846-2024-26-2-31-39
345. Nadeem, M. S., Murtaza, B. N., Al-Ghamdi, M. A., Ali, A., Zamzami, M. A., Khan, J. A., Ahmad, A., Rehman, M. U., & Kazmi, I. (2021). Autism - A Comprehensive Array of Prominent Signs and Symptoms. Current Pharmaceutical Design. https://doi.org/10.2174/1381612827666210120095829
346. Nafisa, D., & Kakunje, A. (2021). Aripiprazole-induced obsessive–compulsive symptoms. Industrial Psychiatry Journal. https://doi.org/10.4103/ipj.ipj_182_20
347. Naidu, B. M. (2016). Drug Abuse in India. International journal of research in social sciences.
348. Nakken, K. O., & Johannessen, S. I. (2008). [Seizure exacerbation caused by antiepileptic drugs].. PubMed.
349. Narváez, V. N. D. P. F., Cortes-Jofre, M., & Ortiz-Muñoz, L. E. (2023). Morfina para el dolor neuropático crónico en adultos. https://doi.org/10.31219/osf.io/4a75b
350. Navarro-Roa, C., Rodríguez‐Violante, M., & Cervantes‐Arriaga, A. (2019). Terapias de infusión en la enfermedad de Parkinson avanzada. DELETED. https://doi.org/10.24875/rmn.m19000018
351. Nechel, V. (2007). [Oculomotor anomalies from medications].. PubMed.
352. Nehretskii, S. (2023). Interdisciplinary Forensic and Pharmaceutical, Organizational and Legal, Clinical and Pharmacological Study of Abuse of Psychoactive Substances. SSP Modern Pharmacy and Medicine. https://doi.org/10.53933/sspmpm.v3i1.85
353. Nemr, K., Simões-Zenari, M., Marques, S. F., Cortez, J. P., & Silva, A. L. D. (2010). Disfonia psicogênica associada a outras doenças: desafio para o tratamento fonoaudiológico**** Psychogenic dysphonia associated to other diseases: a challenge for speech therapy.
354. Neufeld, K. J., Needham, D. M., Oh, E. S., Wilson, L. M., Nikooie, R., Zhang, A., Koneru, M., Balagani, A., Singu, S., Aldabain, L., & Robinson, K. A. (2019). Antipsychotics for the Prevention and Treatment of Delirium. https://doi.org/10.23970/ahrqepccer219
355. Nidode, P., Natarajan, C., Rajathi, G., Deepika, M. R., Shinkre, R., & Chouhan, D. S. (2024). Opioid dependency and intervention: A critical examination of the neurobiological foundations. Multidisciplinary Reviews. https://doi.org/10.31893/multirev.2023ss013
356. Nightall, C. (2018). Emotional reactions to serious diagnosis. Routledge eBooks. https://doi.org/10.4324/9780429474033-3
357. Noble, F., & Roques, B. P. (2003). Inhibitors of Enkephalin Catabolism. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_5
358. Noël, X., Bechara, A., Brevers, D., Verbanck, P., & Campanella, S. (2010). Alcoholism and the Loss of Willpower. Journal of Psychophysiology. https://doi.org/10.1027/0269-8803/a000037
359. Nubli, M. A. (2019). Depresi Pada Penderita Cedera Kepala. https://doi.org/10.35816/jiskh.v10i2.151
360. Nutt, D., & Nestor, L. J. (2018). The opioid system and addiction. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198797746.003.0010
361. Oberbarnscheidt, T., & Miller, N. S. (2015). Mechanisms of Pain and Opioid Pharmacology. Psychiatric Annals. https://doi.org/10.3928/00485713-20151001-06
362. Obeso, J. Á., Guridi, J., & DeLong, M. R. (1997). Surgery for Parkinson's disease.. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.62.1.2
363. Olarte, J. M. N. (2008). Clinical pharmacology of opioids: adverse effects of opioids. CRC Press eBooks. https://doi.org/10.1201/b13440-14
364. Oliveira, J. P. F. L. D., Perin, V. N., & Espósito, S. B. (2021). O uso excessivo de Metilfenidato na infância e os falsos diagnósticos de Transtorno de Déficit de Atenção e Hiperatividade / Childhood Methylphenidate Overuse and Misdiagnosis of Attention Deficit Hyperactivity Disorder. Brazilian Journal of Development. https://doi.org/10.34117/bjdv7n6-517
365. Oliveira, K. K. S. C. D., Taliari, M. A. D. S., Rocha, R. R. D., & Ramos, R. R. (2018). Síncope e lipotimia: emergências clínicas na Odontologia. ARCHIVES OF HEALTH INVESTIGATION.
366. Olié, J., & Lôo, H. (2004). Effets secondaires des antidépresseurs. EMC - Psychiatrie. https://doi.org/10.1016/j.emcps.2004.05.003
367. Olmos-López, A., Ibarra-Aguilar, J., Cornelio-Nieto, J. O., Ocaña-Hernández, L. A., Márquez-Amaya, M. A., Luna-López, N. A., Reséndiz-Aparicio, J. C., & Rodríguez‐Leyva, I. (2019). Clinical guideline: status epilepticus in children and adults. DELETED. https://doi.org/10.24875/rmn.m19000031
368. Olney, A. H., Kolodziej, P., Schaefer, G. B., & Buehler, B. A. (1997). Oral-Facial-Digital Syndrome Type I. Ear Nose & Throat Journal. https://doi.org/10.1177/014556139707601104
369. Olthoff, A. (2018). Erkrankungen der Sprache und des Sprechens im Alter. Laryngo-Rhino-Otologie. https://doi.org/10.1055/a-0652-7074
370. Ornoy, A. (2002). The effects of alcohol and illicit drugs on the human embryo and fetus.. PubMed.
371. Osterman, J. E., Erdos, B. Z., Oldham, M., & Ivkovic, A. (2010). Antidepressant Treatments in PTSD. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-435-7_7
372. Ostwal, S., Salins, N., & Deodhar, J. (2017). Reversal of opioid-induced toxicity. Indian Journal of Palliative Care. https://doi.org/10.4103/ijpc.ijpc_117_17
373. Ozdemir, D., Allain, F., Kieffer, B. L., & Darcq, E. (2023). Advances in the characterization of negative affect caused by acute and protracted opioid withdrawal using animal models. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2023.109524
374. O’Connor, F. G., & Levine, B. D. (2015). Syncope in Athletes of Cardiac Origin. Current Sports Medicine Reports. https://doi.org/10.1097/01.csmr.0000465136.70746.5b
375. O’Shea, J., Law, F., & Melichar, J. (2009). Opioid dependence.. PubMed.
376. Palmer, B. A. (2016). Substance Use Disorders, Personality Disorders, and Eating Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190464868.003.0069
377. Panda, T. K., GOYA, D., Nebhinani, N., & GOYAL, A. (2022). Mania after codeine self-medication in a case of panic disorder. Minerva Psychiatry. https://doi.org/10.23736/s2724-6612.21.02239-9
378. Pang, D., & Pucci, M. (2021). Medical Aspects of Drug and Alcohol Use. Cambridge University Press eBooks. https://doi.org/10.1017/9781911623199.011
379. Pang, N. T. P., & Masiran, R. (2020). Mood disorder induced by prednisolone – an easily overlooked complication. Current Problems of Psychiatry. https://doi.org/10.2478/cpp-2020-0012
380. Papuc, I., LĂCĂTUŞ, R., Timen, A. M., Coşa, L., & Purdoiu, R. C. (2007). CANINE ANXIETY SINDROME BY DOG - OWNER SEPARATION TREATMENT. Bulletin of University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca Veterinary Medicine. https://doi.org/10.15835/buasvmcn-vm:64:1-2:2397
381. Parbalkar, A., Deshmukh, R. A., & Kale, S. S. (2024). PREVALENCE AND OUTCOMES OF DELIRIUM TREMENS IN CONSULTATION-LIAISON PSYCHIATRY. PARIPEX-INDIAN JOURNAL OF RESEARCH. https://doi.org/10.36106/paripex/1300109
382. Partinen, M., Huutoniemi, A., Kajaste, S., Lagerstedt, R., Markkula, J., Mäkinen, E., Paakkari, I., Partonen, T., Polo, P., Saarenpää‐Heikkilä, O., Seppälä, M., Kukkonen-Harjula, K., & Tuunainen, A. (2016). [Update on Current Care Guideline: Insomnia].. PubMed.
383. Patel, A., Moreland, T., Haq, F., Siddiqui, F., Mikul, M., Qadir, H., & Raza, S. (2011). Persistent Psychosis After a Single Ingestion of “Ecstasy” (MDMA). The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01200
384. Patel, B., & Kosten, T. R. (2019). Keeping Up with Clinical Advances: Opioid Use Disorder. CNS Spectrums. https://doi.org/10.1017/s109285291900110x
385. Patricia, G. C. C., AAngela, G.-M., & Marina, R.-A. (2017). Diagnostic and therapeutical challenges of late-onset psychosis.. Journal of Psychology and Cognition. https://doi.org/10.35841/psychology-cognition.2.4.218-220
386. Patro, M., Sah, R. B., & Vaidya, S. (2018). Mirtazapine Induced Parasomnia Overlap Disorder. Indian Journal of Sleep Medicine. https://doi.org/10.5005/jp-journals-10069-0022
387. Pattanashetti, L., & Doddanavar, A. (2022). Alcohol Induced Cerebellar Ataxia: A Case Report. Journal of Young Pharmacists. https://doi.org/10.5530/jyp.2022.14.25
388. Paulin, L. F. R. D. S., Reis, E. F. D., & Rodrigues, E. P. (2008). Síndrome de descontinuação dos antidepressivos.
389. Paulo, S. A. (2024). DELIRIUM EM PACIENTES CRÍTICOS EM UNIDADES DE TERAPIA INTENSIVA: REVISÃO DE LITERATURA. Instituto Produzir eBooks. https://doi.org/10.62363/978-65-84941-21-2.cap23
390. Pavlichenko, A. (2018). Negative symptoms of schizophrenia: the conceptualization and pathophysiological mechanisms. Part 1. Psikhiatriya. https://doi.org/10.30629/2618-6667-2018-77-86-96
391. Pawasauskas, J. (2015). Opioid rotation: A case example using methadone in spinal cord injury. Journal of Opioid Management. https://doi.org/10.5055/jom.2015.0294
392. Pereira, A. K. A., Nogueira, E. C., Brito, E. N. D., Almeida, M. G. D., Nascimento, S. C. D. S., & Santos, S. C. D. (2022). A polifarmácia para o tratamento da epilepsia na rede pública de saúde: uma revisão integrativa de literatura. Research Society and Development. https://doi.org/10.33448/rsd-v11i11.33621
393. Perera-Diltz, D. (2015). Cannabis Use Disorder. https://doi.org/10.63134/refd7106
394. Pergolizzi, J. V., Raffa, R. B., & Rosenblatt, M. (2020). Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. Journal of Clinical Pharmacy and Therapeutics. https://doi.org/10.1111/jcpt.13114
395. Pergolizzi, J. V., Taylor, R., LeQuang, J. A., Bisney, J., Raffa, R. B., Pergolizzi, F., Colucci, D., & Batastini, L. (2018). Driving under the influence of opioids: What prescribers should know. Journal of Opioid Management. https://doi.org/10.5055/jom.2018.0474
396. Phan, S. V. (2016). Medication adherence in patients with schizophrenia. The International Journal of Psychiatry in Medicine. https://doi.org/10.1177/0091217416636601
397. Phu, T., Remmers, A., Schytz, H. W., Schankin, C. J., Nelson, S. E., Obermann, M., Hansen, J. M., Sinclair, A. J., Gantenbein, A. R., & Schoonman, G. (2018). Red and orange flags for secondary headaches in clinical practice. Neurology. https://doi.org/10.1212/wnl.0000000000006697
398. Pies, R. W. (2007). Is It Bipolar Depression? 'WHIPLASHED' Aids Diagnosis. Current psychiatry.
399. Pikirenia, U., Fedotov, I., Tuchina, O., & Kapytau, A. U. (2017). Cognitive impairment due to alcohol abuse: current status of research. Vestnik of Saint Petersburg University Medicine. https://doi.org/10.21638/11701/spbu11.2017.306
400. Plotkin, K. E. (2007). Insomnia Caused by Medical Disorders. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-042-7_15
401. Poewe, W., Olanow, C. W., Rascol, O., & Stocchi, F. (2020). From OFF to ON—Treating OFF Episodes in Parkinson’s Disease. touchREVIEWS in Neurology. https://doi.org/10.17925/usn.2020.16.suppl.1.2
402. Popa, T., & Delcea, C. (2019). Voyeurism and Scopophilia. International Journal of Advanced Studies in Sexology. https://doi.org/10.46388/ijass.2019.12.11.121
403. Popescu, D., Popescu, G., Lupu, G., Panus, V., Neagu-Sadoveanu, S., & Buda, O. (2010). Drugs effects on the central nervous system. Forensic implications. Romanian Journal of Legal Medicine. https://doi.org/10.4323/rjlm.2010.231
404. Popescu, I.-M., & Bourgeois, J. A. (2009). Persistent lithium-induced neurotoxicity: direct effect of lithium and/or hypernatremia?. Jefferson Journal of Psychiatry. https://doi.org/10.29046/jjp.022.1.003
405. Prvčić, I., Zec, M. R., & Barišić, I. (2008). Psychological aspects of learning disabilities. Paediatria Croatica. https://doi.org/10.13112/pc.925
406. Putra, H. G. S. A. (2015). GANGGUAN AFEKTIF BIPOLAR MANIA DENGAN PSIKOTIK: SEBUAH LAPORAN KASUS. DOAJ (DOAJ: Directory of Open Access Journals).
407. Pérez, J. M. V., & Alonso, C. M. (2009). Trastornos del movimiento inducidos por fármacos. Revista de Neurología. https://doi.org/10.33588/rn.48s01.2009039
408. Pérez, S., & Reinaldo, A. (2017). Biomarcadores de estrés e inflamación en la psicosis temprana. TDX (Tesis Doctorals en Xarxa).
409. Pérez, Y. M. M., Ortega, D. L. G., & Torres, S. V. L. (2022). AGITACIÓN PSICOMOTRIZ. PUERTO MADERO EDITORIAL eBooks. https://doi.org/10.55204/pmea.3.c10
410. Pérez-Macho, L., & Borja-Andrés, S. (2010). [Digestive disorders in Parkinson's disease: gastric atony, malabsorption and constipation]..
411. Quartini, A., Pacitti, F., Bersani, G., & Iannitelli, A. (2018). From Adolescent Neurogenesis to Schizophrenia: Opportunities, Challenges and Promising Interventions. Biomedical Reviews. https://doi.org/10.14748/bmr.v28.4452
412. Quintero, J. M. B., Castellanos, A., & Santos, L. S. D. L. (2018). Efectividad de una intervención pre-quirúrgica de enfermería; en ansiedad de pacientes sometidos a colecistectomía del Hospital General Regional No.1 Vicente Guerrero de Acapulco, 2017.
413. Radovanovi, M. R., Milovanovi, D. R., & Radovanovi, M. S. (2012). Heroin addict with gangrene of the extremities, rhabdomyolysis and severe hyperkalemia Heroinski zavisnik sa gangrenom ekstremiteta, rabdomiolizom i teškom hiperkalemijom.
414. RAI, J., Shah, A., Yadav, P., & Chaudhari, M. (2016). Impact of anti-epileptic drugs on cognition: a review. International Journal of Basic & Clinical Pharmacology. https://doi.org/10.18203/2319-2003.ijbcp20161497
415. Ramos, T. M. B., Silva, R. R. D., Xavier, M., Santos, T. S. D., Lira, J. V. D., Costa, S. P., Silva, J. K. D. S., Silva, Á., Pontes, A., Silva, V. M. T., & Júnior, J. U. F. G. (2025). O USO DE PSICOTRÓPICOS RELACIONADO A QUALIDADE DO SONO DA PESSOA IDOSA. Revista Foco. https://doi.org/10.54751/revistafoco.v18n6-202
416. Rani, M. K. S., Fathima, S. T., Gayathri, S. L., Pavani, M., & Swathi, Y. (2022). Detection of Autism Spectrum Disorder using Machine Learning. International Journal of Advanced Research in Science Communication and Technology. https://doi.org/10.48175/ijarsct-7600
417. Rao, S. (2016). Prolonged coma after anesthesia. Journal of Anaesthesiology Clinical Pharmacology. https://doi.org/10.4103/0970-9185.173339
418. Rastegar, D. A. (2020). Opioids. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0006
419. Rastegar, D. A., & Fingerhood, M. (2015). Hallucinogens and Dissociatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0009
420. Razaq, M., Balicas, M., & Mankan, N. (2007). Use of Hydromorphone (Dilaudid) and Morphine for Patients With Hepatic and Renal Impairment. American Journal of Therapeutics. https://doi.org/10.1097/01.pap.0000249926.89087.d8
421. Reid, W. H., Balis, G. U., & Sutton, B. (1997). The treatment of psychiatric disorders : revised for DSM-IV.
422. Reinares, M., Martínez‐Arán, A., & Vieta, E. (2019). Psychoeducation for Patients and Family Members. Cambridge University Press eBooks. https://doi.org/10.1017/9781108589802.004
423. Renemane, L., Vrubļevska, J., & Cera, I. (2022). First Episode Psychosis Following COVID-19 Vaccination: a Case Report.. PubMed.
424. Renzullo, A. M., Benvenuto, S., Nait, G., & Pennesi, M. (2024). L'enuresi notturna: in quadramento e gestione. Medico e Bambino. https://doi.org/10.53126/meb43499
425. Revol, O., & Fourneret, P. (2002). [Diagnostic approach in hyperkinetic children].. HAL (Le Centre pour la Communication Scientifique Directe).
426. Rf, B. (1997). [Practical problems associated with long-term opioid therapy].. PubMed.
427. Riddle, M. A., King, R. A., Hardin, M. T., Scahill, L. D., Ort, S. I., Chappell, P., Rasmusson, A. M., & Leckman, J. F. (1990). Behavioral Side Effects of Fluoxetine in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.1990.1.193
428. Riofrío, I. P. B., Jefe, M., De, D., Mental, S., Miller, H., Mt, S., Psiquiatría, D., Dra, H., Velastegui, G. N. J., medico, Psc, R., Alexandra, C., & Torres, L. (2019). Síndrome Neuroléptico Maligno: A propósito de un caso clínico. https://doi.org/10.36015/cambios.v16.n1.2017.279
429. Rizvi, N., Whitty, M., & Daly, R. J. (2010). Absinthe and suicidality. Irish Journal of Psychological Medicine. https://doi.org/10.1017/s0790966700000914
430. Rn, B., Cohen, G., Mi, L., Simmons-Clemmons, W., & Sunderland, T. (1997). Late-life depression: treatment strategies for primary care practice.. PubMed.
431. Roberts, A. J., & Koob, G. F. (1997). The neurobiology of addiction: an overview.. PubMed.
432. Rodrigues, F. D. A. A. (2022). WHAT HAPPENS IN THE BRAIN OF A PERSON WITH DISORDER. International Journal of Health Science. https://doi.org/10.22533/at.ed.1592442202087
433. Rodríguez, E. O., Esquivel, P. S., & Triana, I. M. (2024). Un panorama actualizado de la dispepsia. Revista médica de Panamá. https://doi.org/10.37980/im.journal.rmdp.20242296
434. Rodríguez, F. D., & Coveñas, R. (2011). Targeting Opioid and Neurokinin-1 Receptors to Treat Alcoholism. Current Medicinal Chemistry. https://doi.org/10.2174/092986711797200444
435. Rodríguez, J. J., Ceballos, P. A. M., Ceballos, D. L. M., & Rodriguez, D. A. E. (2018). Manifestaciones inusuales y tratamiento de la toxicidad sistémica por lidocaína: Reporte de caso. Archivos de Medicina.
436. Rodríguez, J. O. (2008). Aportaciones de aripiprazol en el tratamiento de pacientes agudos con esquizofrenia.. Psiquiatria.com.
437. Ronad, S. V., Patail, C. S., Gondbal, S. H., TC, K., Ronad, M., Pankaja, T., Badesgol, R., & Singhal, P. K. J. (2019). Professionals in metro cities suffer from anxiety disorder. Nursing & Care Open Access Journal. https://doi.org/10.15406/ncoaj.2019.06.00198
438. Ropper, A. H., Young, G. B., & Bolton, C. F. (1997). Coma and Impaired Consciousness: A Clinical Perspective.
439. Rowbotham, D. J., Serrano-Gómez, A., & Heffernan, A. (2008). Clinical pharmacology: opioids. CRC Press eBooks. https://doi.org/10.1201/b13460-4
440. Rubiales, Á. S., Duarte, F. J. B., & Valle, M. L. D. (2015). Es necesario precisar el concepto de sedación. Cuadernos de bioética/Cuadernos de bioética.
441. Rubleva, Y. V., Efimenko, A. P., Kukina, N. V., Yurchenko, А. V., Kovaleva, I. I., & Alekseeva, G. (2024). Ototoxicity caused by anti-epileptic drugs. S S Korsakov Journal of Neurology and Psychiatry. https://doi.org/10.17116/jnevro202412412114
442. Ruiz, C. B., Torralbo, M. B., Garcia, R. R., Llobet, A. H., Fernández, I. A., Nielsen, N. P., Landeo, A. R., Ramírez, M. M., Fuentes, D. G., Soler, M. A., & Cañete, J. (2020). Psicosis dual y cariprazina. Caso clínico. LIBRO COMUNICACIONES. https://doi.org/10.17579/sepd2020p141
443. Ružić, M. (2016). Poremećaj glasa kod osoba treće životne dobi.
444. Sadikin, A., & Linda, N. (2018). PENYALAHGUNAAN NARKOBA DAN PSIKOTROPIKA DI KALANGAN REMAJA.
445. Sahoo, M. K., & Biswas, H. (2021). Disulfiram-induced seizure in a patient with alcohol dependence syndrome. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_149_20
446. Saifuddin, T. M., Wei, C. W., Ismail, A. F., & Harun, N. A. (2018). Alcohol-Induced Psychotic Disorder with Suicidal Attempt: A Case Report. The Malaysian journal of psychiatry.
447. Salaspuro, M. (2009). [Intoxicated patient at the emergency department and referral to treatment].. PubMed.
448. Salazar, J. Z., Urrea, S. L., Tuirán, L. C. V., Solarte, D. M. E., Roldán, J. F. O., Ojeda, A. N. E., Motta, J. A. S., Guerrero, A. X. R., & García, O. A. B. (2024). Síndrome de Abstinencia a los Opioides. Ciencia Latina Revista Científica Multidisciplinar. https://doi.org/10.37811/cl_rcm.v8i6.15033
449. Salazar, J. Z., Urrea, S. L., Tuirán, L. C. V., Solarte, D. M. E., Roldán, J. F. O., Ojeda, A. N. E., Motta, J. A. S., Guerrero, A., & García, O. A. B. (2024). Síndrome De Abstinencia A Los Opioides. Ciencia Latina Revista Científica Multidisciplinar. https://doi.org/10.37811/cl_rcm.v8i6.14547
450. Salazar, W. B. P., Israe, C. M. L. G., Antonio, V. V. R., Sofía, S. S. F., & Austreberto, I. Q. R. (2023). Hyperactive and Hypoactive Delirium: What we know so Far. International Journal of Medical Science and Clinical Research Studies. https://doi.org/10.47191/ijmscrs/v3-i7-04
451. Saleh, S. C. (2023). Anesthesia-Related in Recovery Room Complication: Coma and Delayed Emergence. Jurnal Komplikasi Anestesi. https://doi.org/10.22146/jka.v1i1.5532
452. Salkind, A. R. (1997). Coma From Long-term Overingestion of Isoniazid. Archives of Internal Medicine. https://doi.org/10.1001/archinte.1997.00440420156017
453. Salokangas, R. K. R., & McGlashan, T. H. (2008). Early detection and intervention of psychosis. A review. Nordic Journal of Psychiatry. https://doi.org/10.1080/08039480801984008
454. Sandhu, H., Underwood, M., Furlan, A. D., Noyes, J., & Eldabe, S. (2018). What interventions are effective to taper opioids in patients with chronic pain?. BMJ. https://doi.org/10.1136/bmj.k2990
455. Sanz, G. L., Ruíz, E. C., & Vázquez, L. S. (2015). Síndrome confusional ag udo en pacientes de edad avanzada con fractura de fémur. Ágora de enfermería.
456. Saper, J. R., & Lake, A. E. (2008). Continuous Opioid Therapy (COT) is Rarely Advisable for Refractory Chronic Daily Headache: Limited Efficacy, Risks, and Proposed Guidelines. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2008.01153.x
457. Sarkar, S. (2017). Psychiatric comorbidities, oral health, and comprehensive care. Oral Health and Care. https://doi.org/10.15761/ohc.1000113
458. Sarkar, S., Bhatia, G., & Dhawan, A. (2023). Clinical Practice Guidelines for Assessment and Management of Patients with Substance Intoxication Presenting to the Emergency Department. Indian Journal of Psychiatry. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_490_22
459. Sayeed, N., Kumar, V., & Muhammed, S. T. (2024). Neuropsychological Functioning in Patients with Opioids Dependence during Early Abstinence: A Comparative Study. Eastern Journal of Psychiatry. https://doi.org/10.5005/jp-journals-11001-0074
460. Schaefer, C., Tome, M. E., & Davis, T. P. (2017). The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse. Fluids and Barriers of the CNS. https://doi.org/10.1186/s12987-017-0080-3
461. Schneir, A., & Clark, R. F. (2007). The Role of Illicit Drug Use in Sudden In-Custody Death. Humana Press eBooks. https://doi.org/10.1007/978-1-59745-015-7_6
462. Schuckit, M. A. (2016). Treatment of Opioid-Use Disorders. New England Journal of Medicine. https://doi.org/10.1056/nejmra1604339
463. Schulkens, J. E. M., Ibirane, J., Alphen, S. V., & Sobczak, S. (2019). Farmacotherapie bij ouderen met persoonlijkheidsstoornissen: een nieuw aandachtsgebied. Tijdschrift voor Gerontologie en Geriatrie. https://doi.org/10.36613/tgg.1875-6832/2019.03.01
464. Schweitzer, J. B. (2010). Attention‐Deficit/Hyperactivity Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0096
465. Scotton, W. J., Hill, L. J., Williams, A., & Barnes, N. M. (2019). Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions. International Journal of Tryptophan Research. https://doi.org/10.1177/1178646919873925
466. Sejdić, E., Malandraki, G. A., & Coyle, J. L. (2018). Computational Deglutition: Using Signal- and Image-Processing Methods to Understand Swallowing and Associated Disorders [Life Sciences]. IEEE Signal Processing Magazine. https://doi.org/10.1109/msp.2018.2875863
467. Sekhon, S., Patel, J., & Sapra, A. (2019). Late Onset Depression. StatPearls.
468. Serageldin, M., Hikmet, W., & Alani, S. (2019). Insomnia is a Prodromal Symptom for Psychosis. Journal of the Bahrain Medical Society. https://doi.org/10.26715/jbms.31_31012019
469. Serrano, L., & Néstor, A. (2019). Proceso de Atención de Enfermería en neonato con diagnóstico de Síndrome de Abstinencia Neonatal, perteneciente al área CIN en el Hospital General Guasmo Sur..
470. Sh.H., S., L.A., T., N.I., K., V.K., A., & Nurkhodjaev, S. (2020). Diagnostics of Dysthymic Disorders and Therapy of Patients with Opium Addiction with AnxietyDepressive Variant of Post-Withdrawal Syndrome. International Journal of Current Research and Review. https://doi.org/10.31782/ijcrr.2020.122320
471. Sharma, S., Kumar, P., Raut, N., & Prasad, S. (2021). Psychotic symptoms in heroin withdrawal: A case report. Indian Journal of Case Reports. https://doi.org/10.32677/ijcr.2021.v07.i02.010
472. Sharma, S., Kumar, P., Singh, R., Sidhu, G., & Shah, K. (2021). Psychotic Symptoms in Heroin Withdrawal: A Case Report. Cureus. https://doi.org/10.7759/cureus.12620
473. Sheets, E. S., & Brosse, A. L. (2010). Major Depressive Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0522
474. SheikhBahaei, S., Farhan, M., & Maguire, G. A. (2022). Improvement of stuttering after administration of methylphenidate - a case report. Personalized Medicine in Psychiatry. https://doi.org/10.1016/j.pmip.2022.100092
475. Shiguango, J. A. O., Cárdenas, M. G. P., Calvopiña, G. C. A., Maza, X. M. S., Segovia, K. X. V., Reyes, L. A. J., Flores, D. P. Z., Montenegro, G. P. H., & Cedeño, S. D. D. (2020). Tratamiento del delirium en pacientes en cuidados intensivos. Archivos venezolanos de farmacología y terapéutica.
476. Shiguango, J. A. O., Cárdenas, M. G. P., Calvopiña, G. C. A., Maza, X. M. S., Segovia, K. X. V., Reyes, L. A. J., Flores, D. P. Z., Montenegro, G. P. H., & Cedeño, S. D. D. (2020). Tratamiento del delirium en pacientes en cuidados intensivos. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.4064961
477. Shinohara, M., & Yamada, M. (2016). [Drug-induced Cognitive Impairment].. PubMed. https://doi.org/10.11477/mf.1416200415
478. Shore, J. H., FRAUNFELDER, F. T., & MEYER, S. M. (1987). Psychiatric Side Effects from Topical Ocular Timolol, a Beta-Adrenergic Blocker. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-198708000-00012
479. Shprecher, D., & Mehta, L. (2010). The syndrome of delayed post-hypoxic  leukoencephalopathy.. PubMed.
480. Shurman, J., Koob, G. F., & Gutstein, H. B. (2010). Opioids, Pain, the Brain, and Hyperkatifeia: A Framework for the Rational Use of Opioids for Pain. Pain Medicine. https://doi.org/10.1111/j.1526-4637.2010.00881.x
481. Sidana, A., Singh, A., Sawal, N., Chavan, B., & Gupta, R. (2020). Neuropsychiatric manifestations of methyl iodide toxicity. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_638_19
482. Silber, T. J. (1987). A Variant of Hoigne's Syndrome Following Intramuscular Cefoxitin Sodium?. Archives of Pediatrics and Adolescent Medicine. https://doi.org/10.1001/archpedi.1987.04460050017008
483. Silva, D. G. C. D., Kanazawa, L. K. S., & Vecchia, D. D. (2019). Schizophrenia: effects of aripiprazole in metabolic syndrome. Brazilian Journal of Pharmaceutical Sciences. https://doi.org/10.1590/s2175-97902019000217840
484. Silva, D. G. C. D., Kanazawa, L. K. S., & Vecchia, D. D. (2019). Schizophrenia: effects of aripiprazole in metabolic syndrome. Figshare. https://doi.org/10.6084/m9.figshare.10073615
485. Silver, R. M., & Airoldi, J. (2016). 27. Inherited thrombophilia. CRC Press eBooks. https://doi.org/10.1201/9781315200910-28
486. Simbolon, N. Y., Sitorus, T. R., Meliala, T. L., & Waruwu, P. (2020). TINJAUAN KRIMINOLOGI TERHADAP ANAK YANG MELAKUKAN TINDAK PIDANA PENYALAHGUNAAN NARKOTIKA. JURNAL ILMIAH SIMANTEK.
487. Singh, G., & Kaur, P. (2017). ANTIPSCYHOTIC INDIAN HERBAL FORMULATIONS: AN OVERVIEW. Indian Research Journal of Pharmacy and Science. https://doi.org/10.21276/irjps.2017.4.1.6
488. Sjoblom, M. D., Gordon, D., & Aronson, L. A. (2018). Hypopituitarism. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190678333.003.0041
489. Slobodin, G., & Odeh, M. (2015). Progressive Brain Atrophy due to Chronic Alcohol Abuse.. PubMed.
490. Smith, A. D., & Aronson, J. K. (2002). Adverse reactions to drugs. https://doi.org/10.1093/oso/9780192632340.003.0009
491. Smith, B. H. (2018). SP0073 Opioid prescribing: what’s the problem?. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2018-eular.7668
492. Smith, G. T., Zapolski, T. C. B., Combs, J. L., & Friend, R. E. (2010). Impulsivity. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0436
493. Smith, H. S., Smith, J. M., & Seidner, P. (2012). Opioid-induced nausea and vomiting.. PubMed. https://doi.org/10.3978/j.issn.2224-5820.2012.07.08
494. Smith, S. S. (2019). Insomnia and Clinical Sleep Disturbance in Later Life. Oxford Research Encyclopedia of Psychology. https://doi.org/10.1093/acrefore/9780190236557.013.419
495. Snyder, C. S. (2010). Refer or reassure: guidance on managing patients with syncope. AAP News. https://doi.org/10.1542/aapnews.2010315-18
496. Soares, E. B., Pires, J. B., Menezes, M. D. A., Santana, S. K. S. D., & Fraga, J. (2010). Fonoaudiologia X ronco/apneia do sono. Revista CEFAC. https://doi.org/10.1590/s1516-18462010000200019
497. Sochacki, S. (2025). Hyperalgesia, allodynia, and eventual overdose: The problems with chronic opioid use. Journal of Opioid Management. https://doi.org/10.5055/jom.0891
498. Solimini, R., Rotolo, M. C., Pichini, S., & Pacifici, R. (2017). Neurological Disorders in Medical Use of Cannabis: An Update. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527316666170413105421
499. Solmi, M., Bortolato, B., Veronese, N., Stubbs, B., Herrmann, N., & Carvalho, A. F. (2019). Pharmacological Interventions for Cognitive Dysfunction in Major Depressive Disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198810940.003.0018
500. Sonies, B. C. (1997). Swallowing Disorders and Rehabilitation Techniques. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1097/00005176-199700002-00016
501. Sordi, A. O., Schuch-Goi, S. B., & Diemen, L. V. (2019). Substance abuse and neuroprogression. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198787143.003.0012
502. Soyka, M. (2009). Psychotische Störungen durch Alkohol. Nervenheilkunde. https://doi.org/10.1055/s-0038-1628675
503. Spanagel, R., Tran, B. X., Reyes‐Gibby, C. C., DeBeck, K., Ibrahim, F., & Bonevski, B. (2016). Advances in Drug Addiction.
504. Sparmann, M., & Müller, D. (2017). Ungewöhnliche attackenweise Einschlafstörungen Unusual attack-like sleep onset disturbances. Nervenheilkunde. https://doi.org/10.1055/s-0038-1627037
505. Spina, S. P., & Corrigan, S. P. (2007). Continuing Clozapine Therapy Despite Morning Pseudoneutropenia. The Canadian Journal of Hospital Pharmacy. https://doi.org/10.4212/cjhp.v60i4.188
506. Stahl, S. M., & Morrissette, D. A. (2018). Treatment of Secondary Behavioral Symptoms of Dementia. https://doi.org/10.1017/9781107706842.008
507. Stankewicz, H., Richards, J. R., & Salen, P. (2017). Alcohol Related Psychosis. StatPearls.
508. Steefan, J. M., Siddesha, G., & Naveen, A. (2023). Adverse Effects of Antipsychotic Drugs - A Review. International Journal of Research and Review. https://doi.org/10.52403/ijrr.20230916
509. Stein, C. (1997). Opioid Treatment of Chronic Nonmalignant Pain1. Anesthesia & Analgesia. https://doi.org/10.1097/00000539-199704000-00038
510. Stein, C. (1997). Opioid Treatment of Chronic Nonmalignant Pain1. Anesthesia & Analgesia. https://doi.org/10.1213/00000539-199704000-00038
511. Stein, D. J., Honk, J. V., Ipser, J., Solms, M., & Panksepp, J. (2007). Opioids:<i>From Physical Pain to the Pain of Social Isolation</i>. CNS Spectrums. https://doi.org/10.1017/s1092852900021490
512. Sternbach, H., & State, R. C. (1997). Antibiotics: Neuropsychiatric Effects and Psychotropic Interactions. Harvard Review of Psychiatry. https://doi.org/10.3109/10673229709000304
513. Stewart, J. L., May, A. C., & Paulus, M. P. (2019). Bouncing back: Brain rehabilitation amid opioid and stimulant epidemics. NeuroImage Clinical. https://doi.org/10.1016/j.nicl.2019.102068
514. Stone, J., Pal, S., Blackburn, D., Reuber, M., Thekkumpurath, P., & Carson, A. (2015). Functional (Psychogenic) Cognitive Disorders: A Perspective from the Neurology Clinic. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-150430
515. Su, R. (2007). Effect of acute opioid treatment on learning and memory. Journal of Pharmaceutical Research.
516. Subramonian, A., & Featherstone, R. (2020). Interventions for the Prevention of Sudden Infant Death Syndrome and Sudden Unexplained Death in Infancy: A Review of Guidelines [Internet].
517. Sumiyoshi, T., Matsuoka, T., & Kurachi, M. (2012). Role for Pituitary Neuropeptides in Social Behavior Disturbances of Schizophrenia. InTech eBooks. https://doi.org/10.5772/52326
518. Sunshine, A. B., & McClellan, J. (2023). Practitioner Review: Psychosis in children and adolescents. Journal of Child Psychology and Psychiatry. https://doi.org/10.1111/jcpp.13777
519. Swayamprava, S., Giri, H. C., Ojha, S. K., & Niranjan (2024). Understanding of Alcohol use disorder in Ayurveda. International Journal For Multidisciplinary Research. https://doi.org/10.36948/ijfmr.2024.v06i05.27493
520. Taylor, J. L., & Samet, J. H. (2022). Opioid Use Disorder. Annals of Internal Medicine. https://doi.org/10.7326/aitc202201180
521. Thakkar, K., Shah, K., Rana, D., Malhotra, S., & Patel, P. (2017). Amlodipine drug therapeutic failure: a rare case report. International Journal of Basic & Clinical Pharmacology. https://doi.org/10.18203/2319-2003.ijbcp20175700
522. Thakrar, A. P., & Rastegar, D. A. (2025). Opioids. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197796207.003.0006
523. Thies, T., Muecke, D., Lowit, A., Kalbe, E., Steffen, J., & Barbe, M. T. (2019). Cognitive skills and prominence production : highlighting prominent elements in the speech of patients with Parkinson's disease.
524. Timour, Q., Frassati, D., Descotes, J., Chevalier, P., Christé, G., & Chahine, M. (2012). Sudden Death of Cardiac Origin and Psychotropic Drugs. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2012.00076
525. Todd, O., & Teale, E. (2017). Delirium: a guide for the general physician. Clinical Medicine. https://doi.org/10.7861/clinmedicine.17-1-48
526. Todorović, S. (2016). Socijalno medicinske karakteristike i razlike između alkoholičara sa periodičnim i kontinuiranim pijenjem / Social and Medical Characteristics and Differences Between Alcoholics With Periodic and Continuous Drinking. SESTRINSKI ŽURNAL. https://doi.org/10.7251/sez0116005t
527. Tondo, L., & Baldessarini, R. J. (2020). Discontinuing psychotropic drug treatment. BJPsych Open. https://doi.org/10.1192/bjo.2020.6
528. Toro, V. D., Aedo, K., & Urrejola, P. (2021). Trastorno de Evitación y Restricción de la Ingesta de Alimentos (ARFID): Lo que el pediatra debe saber. Andes pediatrica. https://doi.org/10.32641/andespediatr.v92i2.2794
529. Torpy, J. M. (2010). Delirium. JAMA. https://doi.org/10.1001/jama.304.7.814
530. Trachsel, M., Irwin, S. A., & Chochinov, H. M. (2024). [Anxiety and fear at the end of life].. PubMed. https://doi.org/10.23785/tu.2024.04.003
531. Trachtenberg, E., Passos, I. C., Kleina, W. W., Sica, D. R. D. N., & Fleck, M. P. D. A. (2012). Hypothyroidism and Severe Neuropsychiatric Symptoms: A Rapid Response to Levothyroxine. Brazilian Journal of Psychiatry. https://doi.org/10.1016/j.rbp.2012.04.003
532. Trachtenberg, M. C., & Blum, K. (1987). Alcohol and Opioid Peptides: Neuropharmacological Rationale for Physical Craving of Alcohol. The American Journal of Drug and Alcohol Abuse. https://doi.org/10.3109/00952998709001520
533. Trill, M. D. (2012). Psychological aspects of depression in cancer patients: an update. Annals of Oncology. https://doi.org/10.1093/annonc/mds350
534. Trujillo, K. A. (2002). The Role of NMDA Receptors in Opiate Tolerance, Sensitization, and Physical Dependence. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_20
535. Tsai, L., & Liou, H. (2015). Current Treatment for Generalized Convulsive Status Epilepticus in Adults.. PubMed.
536. Turki, T. (2002). The Emergence of Agitation and Suicide Ideation Secondary to the use of Fluoxetine Therapy: A Case Report. Journal of King Abdulaziz University-Medical Sciences. https://doi.org/10.4197/med.10-1.12
537. Turki, T. A. A., & Arabia, S. (2002). The Emergence of Agitation and Suicide Ideation Secondary to the use of Fluoxetine Therapy: A Case Report.
538. Uddin, M. S., Sufian, M. A., Kabir, M. T., Hossain, M. F., Nasrullah, M., Islam, I., Mamun, A. A., Islam, M. T., & Khanum, S. (2017). Amphetamines: Potent Recreational Drug of Abuse. Journal of Addiction Research & Therapy. https://doi.org/10.4172/2155-6105.1000330
539. Uhrhan, T., Gövercin, M., & Schaefer, M. (2010). [The effect of medications on the risk of falling in elderly patients].. PubMed.
540. Urazán, D. T., Barragán, A. G., Hernández, K. D. C. P., & Gamboa, D. J. (2023). Afasia primaria progresiva variante no fluente/agramática. Acta neurológica colombiana. https://doi.org/10.22379/anc.v39i3.853
541. Vadivelu, N., Mitra, S., Kai, A., Kodumudi, G., & Gritsenko, K. (2016). Review of perioperative pain management of opioid-dependent patients. Journal of Opioid Management. https://doi.org/10.5055/jom.2016.0344
542. Val, C. V. D. (2021). El recién nacido con encefalopatía hipóxico-isquémica perinatal en la era de la hipotermia terapéutica. https://doi.org/10.35376/10324/59939
543. Varelas, P. N., & Jones, M. (2017). Antiepileptic Drugs in the Neurosurgical Intensive Care. Current Pharmaceutical Design. https://doi.org/10.2174/1381612823666171030150437
544. Vasconcelos, L. P. B., Gandini, J., Teixeira, A., & Manto, M. (2022). Movement Disorders Associated With Stimulants and Other Drugs of Abuse. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197574317.003.0009
545. Velasco-Rey, M. C., Sánchez-Muñoz, M., Lopez, M., Trujillo-Borrego, A., & Sánchez-Bonome, L. (2012). Psychotic depression induced by Obstructive Sleep Apnoea Syndrome (OSAS): a case reported.. PubMed.
546. Vendruscolo, L. F., & Koob, G. F. (2019). Alcohol Dependence Conceptualized as a Stress Disorder. https://doi.org/10.1093/oxfordhb/9780190681777.013.9
547. Venkataraman, R., Patodia, S., & Thiriveedhi, R. N. (2023). Thrombocytopenia in the Critically Ill: An Animal with Several Heads. Indian Journal of Critical Care Case Report. https://doi.org/10.5005/jp-journals-11006-0089
548. Vergano, S. A. S., Sluijs, P. J. V. D., & Santen, G. W. (2019). ARID1B-Related Disorder.
549. Vezzosi, D., Bennet, A., Maïza, J.-C., Buffet, A., Grunenwald, S., Fauvel, J., Courbon, F., Otal, P., Carrère, N., & Caro, P. (2011). Diagnosis and Treatment of Insulinomas in the Adults. InTech eBooks. https://doi.org/10.5772/17452
550. Vicente, M. O., Gutiérrez, L. E. J. F., & Oves, M. I. R. (2011). ALCOHOLISMO CONSECUTIVO AL TRASTORNO DE PÁNICO. DOAJ (DOAJ: Directory of Open Access Journals).
551. Vidić, M. (2018). Psihološki aspekti ovisnosti o psihoaktivnim tvarima.
552. Villota, J. A. O., Bohorquez, G. D. B., Martínez, L. J. M., Vides, L. M. Á., Avilez, M. L. B., Ramírez, A. F., Ortega, J. E. P., & Suescun, G. C. (2022). Heart shock secondary to the use of clozapine. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2022.13.3.0211
553. Voon, V., Thomsen, T., Miyasaki, J. M., Souza, M. D., Shafro, A., Fox, S. H., Duff‐Canning, S., Lang, A. E., & Zurowski, M. (2007). Factors Associated With Dopaminergic Drug–Related Pathological Gambling in Parkinson Disease. Archives of Neurology. https://doi.org/10.1001/archneur.64.2.212
554. Vuković, V., Lalić, S. N., Voskresenski, T., & Jokić, S. (2016). Kraepelin's ghost: Late onset schizophrenia, dementia (non)praecox, or paraphrenia? (case report). European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1982
555. Wahyuningsih, S., Nurun, N., Ainul, A., Rendra, R., & Dwiki, D. (2020). Relaksasi Nafas Dalam Terhadap Tingkat Kecemasan Pada Lansia Yang Menderita Hipertensi Di RT 03 RW 09 Kelurahan Slipi Palmerah Jakarta Barat. JURNAL KREATIVITAS PENGABDIAN KEPADA MASYARAKAT (PKM). https://doi.org/10.33024/jkpm.v3i2.3194
556. Walker, M. L., Patel, K., Li, T., & Kassir, M. (2021). Opioid-Associated Amnestic Syndrome. Cureus. https://doi.org/10.7759/cureus.20056
557. Wang, W., Hu, W., Tian, J. Y., Wang, X., & Wang, Z. (2023). The role of sevoflurane in postoperative cognitive dysfunction. Medical Gas Research. https://doi.org/10.4103/2045-9912.388755
558. Weaver, M. (2018). Substance-Related Disorders. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615371990.jl16
559. Weaver, M. F., Heads, A. M., & Faillace, L. A. (2024). Mood Disorders and Comorbid Substance Use Disorders. Cambridge University Press eBooks. https://doi.org/10.1017/9781108973922.013
560. Wenbing, C., Asano, T., Notaka, I., Shin-Ichi, M., & Nitta, A. (2025). SUPPRESSION OF TENEURIN-4 IN THE NUCLEUS ACCUMBENS ALLEVIATES METHAMPHETAMINE-INDUCED DOPAMINE RELEASE AND BEHAVIORAL ALTERATIONS IN MICE. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae059.174
561. Wesson, D. R., Smith, D. E., Ling, W., & Sabnani, S. (2008). Substance Abuse: Sedative, Hypnotic, or Anxiolytic Use Disorders. Psychiatry. https://doi.org/10.1002/9780470515167.ch64
562. Wetmore, L. A. (2018). Opioids. https://doi.org/10.1002/9781119028994.ch194
563. Wijdicks, E. F. M. (2025). Neurology of Overdose. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197544976.003.0052
564. Wikler, A. (1980). Opioid Dependence: Mechanisms and Treatment.
565. Williams, M. D. (2018). Dynamique de l’excitabilité corticale dans l’épilepsie-absence et intégration sensorielle.
566. Williams, R. H., & Erickson, T. B. (2000). Emergency Diagnosis of Opioid Intoxication. Laboratory Medicine. https://doi.org/10.1309/qy8t-kgbn-bva6-h706
567. Williams, R. H., & Erickson, T. B. (2000). Evaluating Hallucinogenic or Psychedelic Drug Intoxication in an Emergency Setting. Laboratory Medicine. https://doi.org/10.1309/v3j8-3kw2-bpt1-fu15
568. Winbigler, B. L., & Chyka, P. A. (2022). Chapter 43: Substance Misuse and Toxicology. The American Pharmacists Association eBooks. https://doi.org/10.21019/9781582123615.ch43
569. Winger, G., Woods, J. H., & Hofmann, F. G. (2004). Central Nervous System Stimulants: Cocaine, Amphetamines, Related Drugs, and Caffeine. https://doi.org/10.1093/oso/9780195172782.003.0008
570. Winter, B. Y. D., Prell, T., Axer, H., Witte, O. D., & Großkreutz, J. (2010). Acute Disturbance of Axonal Excitability after controlled Alcohol Intake. Klinische Neurophysiologie. https://doi.org/10.1055/s-0030-1251021
571. Winters, K. C., & Ingwalson, A. (2022). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0005
572. Wittmann, M., Back, C. A., & Haen, E. (2010). Verwirrtheitszustände als wichtige Arzneimittelwirkung. Therapeutische Umschau. https://doi.org/10.1024/0040-5930/a000116
573. Wiśniewski, M., Anand, J. S., Chodorowski, Z., & Kosińska-Tomczyk, H. (2007). [Tiagabine overdose--report of two cases].. PubMed.
574. Woo, S., & Keatinge, C. (2016). Neurodevelopmental Disorders I: Autism Spectrum Disorder. https://doi.org/10.1002/9781394259472.ch4
575. Wr, Y., Meller, W. H., & Ep, T. (1987). Behavioral complications of alcoholism.. PubMed.
576. Wyatt, J. P., Illingworth, R. N., Graham, C. A., Hogg, K., Clancy, M., & Robertson, C. E. (2012). Environmental emergencies. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199589562.003.0006
577. Wyatt, R. J. (1986). The dopamine hypothesis: variations on a theme (II).. PubMed.
578. Yang, S., & Werner, B. C. (2018). Risk Factors for Prolonged Postoperative Opioid Use After Spinal Fusion for Adolescent Idiopathic Scoliosis. Journal of Pediatric Orthopaedics. https://doi.org/10.1097/bpo.0000000000001139
579. Yarlagadda, A. R., Brown, A. B., & Clayton, A. H. (2007). Onset of Obstructive Sleep Apnea After Initiation of Psychotropic Agents. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611h
580. Yeragani, V. K. (2002). Cardiac Side Effects of Psychotropic Medications in Children and Adolescents. CRC Press eBooks. https://doi.org/10.1201/9780203909294-12
581. Yoshimura, R., Hori, H., Katsuki, A., & Atake, K. (2016). Marked Improvement of Meige Syndrome in a Japanese Male Patient with Schizophrenia After Switching from Risperidone to Paliperidone: A Case Report. Journal of UOEH. https://doi.org/10.7888/juoeh.38.233
582. Young, W. B., Packard, R. C., & Katsarava, Z. (2007). Headaches Associated with Head Trauma. https://doi.org/10.1093/oso/9780195326567.003.0016
583. Yustiana, A. V., & Aryani, L. N. A. (2019). Gangguan psikotik akibat penggunaan ganja (cannabis): studi kasus. Medicina Journal. https://doi.org/10.15562/medicina.v50i2.123
584. Zaoui, A., Abdelghani, A., Salem, H. B., Ouanes, W., Hayouni, A., Khachnaoui, F., Rejeb, N., & Benzarti, M. (2012). Early-onset severe isoniazid-induced motordominant neuropathy: a case report. Eastern Mediterranean Health Journal. https://doi.org/10.26719/2012.18.3.298
585. Zdybel, M., Rdzanek, B. J., & Skrzypek, W. (2025). OBSESSIVE COMPULSIVE DISORDER - A REVIEW OF TREATMENT METHODS. International Journal of Innovative Technologies in Social Science. https://doi.org/10.31435/ijitss.3(47).2025.3714
586. Zheng, Z., Zou, K., Huang, J., Yang, J., Zhou, J., Xiong, R., & Li, Y. (2023). Schizophrenia. https://doi.org/10.1007/978-981-99-4538-2_20
587. Zhu, X., Zhang, J., & Li, M. (2012). [Decreased sound tolerance and tinnitus].. PubMed.
588. Zoorob, R., Kowalchuk, A., & Grubb, M. D. (2018). Buprenorphine Therapy for Opioid Use Disorder.. PubMed.
589. Zutshi, A., Math, S. B., & Reddy, Y. C. J. (2007). Escitalopram in Obsessive-Compulsive Disorder. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611c
590. Šostar, Z., Vodanović, M., Breitenfeld, D., Breitenfeld, T., Buljan, D., & Granić, R. (2009). Composers - Substance Abusers. Alcoholism and psychiatry research Journal on psychiatric research and addictions.